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 Methicillin-resistant Staphylococcus aureus (MRSA) is a growing concern in 
the medical industry due to high morbidity and difficulty of treatment in infected 
patients. Conventional β-lactam antibiotics kill Staphylococcus aureus bacteria by 
inhibiting the function of cell-wall penicillin binding proteins (PBPs). However, β-
lactams are ineffective against MRSA due to an extra PBP (PBP2a) that has a low 
binding affinity for β-lactam antibiotics. Branched polyethylenimine (BPEI), a non-
toxic, cationic polymer, restores MRSA’s susceptibility to β-lactam antibiotics 
including oxacillin, ampicillin, imipenem, ceftizoxime, and piperacillin. Checkerboard 
assays with MRSA demonstrated synergy between BPEI and β-lactam antibiotics. BPEI 
and oxacillin were effective against MRSA USA300, MRSA MW2, MRSA 700787, 
and clinical isolates of MRSA. A time-killing curve showed BPEI in combination with 
oxacillin to be bactericidal. BPEI did not potentiate vancomycin, chloramphenicol, or 
linezolid against MRSA. Additionally, the BPEI:β-lactam efficacy was specific to 
MRSA and was not observed against methicillin-susceptible Staphylococcus aureus 
(MSSA), Gram-negative Escherichia coli, or Bacillus subtilis.  
 When exposed to BPEI, MRSA cells increased in size and had difficulty 
forming septa. Nuclear magnetic resonance (NMR) data show that BPEI alters the 
teichoic acid chemical environment, an anionic polymer found in the cell wall of Gram-
positive bacteria. Laser scanning confocal microscopy (LSCM) images depict BPEI 
residing on the MRSA cell wall, where teichoic acids and PBPs are located. BPEI 
electrostatically binds to wall teichoic acid (WTA), a polymer that is important for 
localization of certain cell wall proteins. BPEI does not potentiate ampicillin or 
xxi 
oxacillin when WTA is removed from the cell by genetic mutation or chemical 
inhibition of WTA synthesis. Using LSCM, we found that BPEI also prevents proper 
localization of PBP4, another PBP that aids in β-lactam resistance. Since PBP4 and 
PBP2a require WTA to properly localize in MRSA, in situ disabling of WTA using 
BPEI inhibits proper orientation and functioning of the enzymes. PBP2a requires 
teichoic acid to properly locate and orient the enzyme, and thus MRSA is susceptible to 
antibiotics that prevent teichoic acid synthesis in the bacterial cytoplasm. These data 
suggest that BPEI may prevent proper localization of cell wall machinery by binding to 
WTA and leading to cell death when administered in combination with β-lactam 
antibiotics. By creating steric hindrance through WTA binding, BPEI in combination 




Chapter 1: Methicillin-resistant Staphylococcus aureus 
 Methicillin-resistant Staphylococcus aureus (MRSA) is a dangerous pathogen 
that causes Staph infections in humans that are difficult to treat. Conventional 
antibiotics, such as ampicillin, are unable to effectively treat MRSA. Consequently, 
amputation of the infected areas and drugs of last resort, vancomycin for instance, are 
leading treatment options. However, MRSA can also spread in the bloodstream, infect 
the heart and other internal organs, and cause sepsis. One in seven patients infected with 
MRSA die from their infection.(1) The Centers for Disease Control designate MRSA as 
a “serious threat.”(2) Thus, a strong need exists to design and create new drugs that can 
effectively kill MRSA in the early stages of infection. My research involves branched 
polyethylenimine (BPEI), a non-toxic polymer that we found restores MRSA’s 
susceptibility to conventional antibiotics, such as oxacillin and ampicillin. BPEI in 
combination with ampicillin and other antibiotics effectively prevents growth of 
MRSA. Additional research I have conducted includes determining BPEI’s mechanism 
of action and understanding how BPEI removes MRSA’s resistance factor. This 
research has been published in the Journal of Antibiotics and ACS Medicinal Chemistry 
Letters.(3, 4) It is our hope, that in the future, BPEI will be used as a first-line treatment 
for MRSA infections. 
 
Antibiotic Resistance 
 Antibiotic resistance is a growing concern in health communities. For many 
decades, the development of antibiotics to kill microbe infections saved millions of 
lives. Since the discovery of antibiotics, bacteria and other microbes have developed 
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resistance to those life-saving drugs. Antibiotic resistance refers to the ability of 
microbes, such as bacteria, to mutate in such a way that allows them to survive in the 
presence of different antibiotics. The Review on Antimicrobial Resistance predicts that 
by the year 2050, antibiotic-resistant superbugs will cause 10 million deaths annually, 
surpassing the number of annual deaths caused by cancer.(5) Overall, 2,049,442 drug-
resistant infections occur each year in the United States alone.(2) Of those, 23,488 result 
in death; about 11,000 of which are caused by MRSA infections.(2) Globally, the 
burden is even worse: 700,000 deaths each year are attributed to antimicrobial-resistant 
pathogens.(5) Of the antibiotic-resistant pathogens, MRSA has the highest death to 
infection ratio (approximately 1:7).(2) Also, antibiotic resistance causes a $55 billion 
economic burden in the United States each year.(6) Since the initial discovery of 
antibiotics, overuse and improper use of antibiotics, as well as poor patient medication 
adherence, have sped up the evolution of resistant species.(7) Estimates state that 30% 
to 50% of prescribed antibiotics are ineffective.(8) Although certain steps can be taken 
to slow the development and prevalence of antibiotic-resistant pathogens, the evolution 
of resistance factors will inevitably outpace the current rate of development of new 
antibiotics. In order to reduce the current and future burden of antibiotic resistance, 
more treatment options must be discovered.  
 Although there is a call to create new antibiotics, only five new classes of 
antibiotics were approved for human use between 2000 and 2015.(9) Of which, the last 
completely new class of antibiotics was daptomycin, discovered in the 1980s.(10-12) 
Most antibiotics that are used today were discovered in the 1940s to 1960s, also known 
as the golden era of antibiotic discovery.(12, 13) Additionally, only one to three new 
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antibiotics were FDA-approved most years between 2000 and 2015.(9) Between 2000 
and 2015, 30 new antibiotics and two new drug combinations were launched.(9) Today, 
pharmaceutical companies tend not to invest in new antibiotic discovery. This is largely 
because diseases cured in a short few days lead to smaller profit margins in comparison 
to other diseases that are longer-lasting or chronic.(14) Also, doctors tend to prescribe 
generic antibiotics to patients, which leads companies to focus on intravenously-
administered antibiotics because these can be given at a higher cost.(14) Other obstacles 
to antibiotic development stem from difficulty in discovering novel compounds or new 
drug targets that can escape the already existing resistance mechanisms.(14) 
Additionally, more focus is placed on discovering antibiotics that have broad-spectrum 
activity since most infections have more than one infecting species.(14) Although 
antibiotics do not require long-term, chronic safety studies, the high dose requirements 
for efficacy causes a hurdle for getting FDA-approval.(14) Therefore, some research 
has focused on repurposing FDA-approved non-antimicrobial drugs for use against 
bacterial infections.(15, 16) Thus, despite the need for new antimicrobial treatments, 
little emphasis has been placed on discovery and development.  
 
Pathogenesis and Prevalence of Staphylococcus aureus 
 The British surgeon Alexander Ogston was the first to report infections caused 
by Staphylococcus bacteria found in abscesses.(17) Staphylococcus aureus, a Gram-
positive pathogen, causes minor to major skin infections as well as life-threatening 
diseases when it infects the blood stream or internal organs (Figure 1). Minor, localized 
skin infections include pimples, abscesses (pus build-up), and folliculitis (infection of 
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hair follicles). Staph skin infections can also be less localized causing impetigo (a 
contagious infection that typically forms red sores in children) or cellulitis (an infection 
of the inner skin layers). The majority of clinical isolates of S. aureus emanate from 
pus-filled chambers in the skin or soft tissues that are isolated from the blood 
system.(18) However, minor infections can become severe in immuno-compromised 
individuals or when spread internally. When S. aureus invades a patient’s bloodstream, 
toxic shock syndrome, bacteremia, and sepsis are possible. Toxic shock syndrome 
occurs when S. aureus releases a superantigen toxin that attacks the immune system of 
healthy patients and often results in death within hours if not treated quickly. 
Bacteremia, the presence of bacteria in the bloodstream, leads to sepsis, which occurs 
when the patient’s immune system injures the host’s tissues while attacking the 
infection. S. aureus is capable of infecting the brain, heart, lungs, and bones, which can 
lead to meningitis, endocarditis, pneumonia, and osteomyelitis, respectively. S. aureus 
can also cause food poisoning. Despite its potential for serious infections, S. aureus 
normally resides in the anterior nares of 20% of healthy individuals.(19) Usually, these 
persistently colonizing bacteria do not negatively impact their host. However, about 
82% of individuals infected with S. aureus are infected by their colonizing strain.(20) 
Colonizing strains provide the host with “protective immunity” and antibodies that help 
prevent toxic shock syndrome; therefore, non-carriers have higher mortality rates than 
carriers.(21, 22)  
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Figure 1. Colonization, infection, and pathogenesis of S. aureus bacteria in the human 
body. 
 
 S. aureus have multiple mechanisms to evade antimicrobials and host defenses 
such as making biofilms, hiding in epithelial cells, forming small-colony variants, and 
creating microcapsules. Each of these mechanisms allows for the bacteria to remain 
undetected by hosts, which makes the bacteria remain viable even after the initial 
infection is cleared.(23-26) Biofilms, groups of bacteria that are embedded in 
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extracellular polymeric substances (EPS), often form on the surfaces of medical 
devices, such as catheters or implants, and are difficult to treat due to the impenetrable 
properties of the EPS layer. Small-colony variants are very slow-growing bacteria that 
can persist in hosts without detection and cause recurrent infections.(25) Sometimes, 
microcapsules form around S. aureus cells, preventing the cells from being killed and 
allowing for adherence to surfaces.(26) By some bacteria being capable of evading cell 
death, S. aureus re-infects the patient and causes recurrent infections after the initial 
treatment. 
 S. aureus is capable of making a variety of toxins and proteins that can attack 
and injure host cells and tissues. One common toxin, Staphylococcal α-toxin, causes 
membrane damage in many different types of host cells, is found in most strains of S. 
aureus, and is considered to be the major cytotoxic agent aiding in virulence.(27) β-
toxin, γ-toxin, and δ-toxin, are similar to α-toxin but attack more specific targets.(28) 
Also, β-toxin does not seem to be active at normal body temperatures; thus, it is not the 
primarily used toxin by S. aureus.(28, 29) The α-, β-, γ-, and δ-toxins all work by 
causing membrane damage and creating pores in host cells. Many of S. aureus’s toxins 
focus on harming host defense cells in order to evade elimination by the immune 
system.(28) Specifically, S. aureus attacks host immune systems through leukocidins, 
which create pores in leukocytes and neutrophils (important immune cells that work to 
kill pathogens) and can induce apoptosis and necrosis.(30) Additionally, S. aureus has 
numerous virulence factors that get released in the infected individual and allow for 
protection, spreading, and quorum-sensing.(19) Also, S. aureus secretes coagulase 
enzymes that clot plasma,(31) deoxyribonucleases that destroy host DNA,(32) and 
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staphylokinases that aid in digesting fibrin to allow spreading of the bacteria.(33) 
MRSA has the same virulence factors as methicillin-susceptible S. aureus (MSSA) with 
the addition of a few others. For example, Panton-Valentine leucocidin (PVL), a pore-
forming toxin, is found in only 5% of S. aureus strains but is frequently found in 
MRSA.(34, 35) MRSA has pathogenicity similar to that of MSSA but cannot be treated 
with conventional β-lactam antibiotics that target the bacterial cell wall.  
  
Bacteria Cell Walls 
 Bacteria are single-cellular organisms that are distinct from mammalian cells 
due to the presence of a complex cell wall that creates structural stability. These 
essential cell walls protect the bacteria and maintain the cell’s morphology. The two 
main types of bacteria, Gram-positive and Gram-negative bacteria, differ in the 
structure of their cell walls (Figure 2). Gram-negative bacteria (such as Escherichia 
coli, Pseudomonas aeruginosa, and Klebsiella pneumonia) have a cytoplasmic 
membrane similar to Gram-positive bacteria covered by a thin peptidoglycan layer. 
Gram-negative bacteria also have an outer membrane that further protects the bacteria. 
The cytoplasmic membrane in bacteria is a phospholipid bilayer that acts as a barrier 
surrounding the entire cell. Eukaryotic cells also have a phospholipid bilayer. 
Peptidoglycan, which is unique to bacteria, strengthens the bacteria by creating a mesh 
of repeating N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM) sugars that 
are crosslinked with amine chains. The periplasmic space, found between the lipid 
membrane and the peptidoglycan, contains a gel-like storage matrix consisting of a high 
concentration of proteins that makes up 20% to 40% of the cell’s volume.(36) The outer 
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membrane of Gram-negative bacteria is composed of phospholipids and 
lipopolysaccharides that prevent many larger molecules from entering the cell and 
periplasm. The outer membrane also imparts a negative charge on the outside of the 
cells. Gram-positive bacteria, such as S. aureus and B. subtilis, have a cytoplasmic 
membrane that is covered by a thick layer of peptidoglycan. Unlike Gram-negative 
bacteria, Gram-positive bacteria do not have an outer membrane. Teichoic acids, 
anionic polymers that attach to either the lipid membrane or the cell wall and extend to 
the extracellular space, are present in Gram-positive bacteria cell walls. The teichoic 
acids impart a negative charge to the bacterial cell wall. The bacteria cell wall is an 
extremely important target for antibiotics because of its uniqueness compared to 





Figure 2. Structure of Gram-positive and Gram-negative bacteria are distinct from one 
another. Gram-positive cell walls have a much thicker peptidoglycan layer and the 
presence of teichoic acids. Gram-negative cell walls have an outer membrane that acts 
as a barrier. 
 
β-Lactam Antibiotics 
 Penicillin, discovered in 1928 accidently by Alexander Fleming, was the first 
antibiotic used to treat Staph infections. Fleming noticed blue-green mold growing on 
his culture of S. aureus, causing a halo of inhibited bacteria growth around it.(37) The 
mold, later isolated and characterized as Penicillium chrysogenum, released penicillin 
into the agar, killing the bacteria. However, issues with the mass production of 
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penicillin prevented it from becoming available to the general public until 1945. Prior to 
the discovery of penicillin, the rate of S. aureus-induced bacteremia was greater than 
80% in infected individuals.(38) Today, β-lactams are still one of the most commonly-
prescribed classes of antibiotics. In fact, approximately 118 million courses of β-lactam 
antibiotics were prescribed to treat bacterial infections in 2011.(39) β-lactam antibiotics 
are favored because of their broad-spectrum activity, specificity for bacteria, and low 
toxicity to humans. 
 Penicillin contains a β-lactam ring, the core component of the β-lactam 
antibiotic group. β-lactam antibiotics function by inhibiting bacteria cell wall 
crosslinking, which is necessary to make the bacterial cell wall strong and robust. 
Penicillin-binding proteins (PBPs) are the proteins responsible for cross-linking the cell 
wall. The β-lactam antibiotics mimic D-alanyl-D-alanine from the precursors of NAG 
and NAM subunits of peptidoglycan. The antibiotic then irreversibly binds to the active 
site of a PBP to inactivate the enzyme. Most species of bacteria have multiple PBPs that 
carry out transpeptidase activity (the crosslinking of peptides), transglycosylate activity 
(the synthesis of glycan strands), and carboxypeptidase activity (the cleaving of the 
peptide bonds that allows construction of the cell wall). All strains of S. aureus carry 
PBP1, PBP2, and PBP3. PBP1 and PBP3 are responsible for transpeptidation. PBP2 is 
responsible for the transglycosylase and transpeptidase activity. PBP4, important for 
resistance in some MRSA strains, has carboxypeptidase and transpepsidase activity. β-
lactam antibiotics cause cell death via cell wall degradation, lysis, and cytoplasm 
leakage.(40) 
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 Since the discovery of penicillin, numerous synthetic and natural derivatives of 
penicillin have been discovered. β-lactam antibiotics are classified into subclasses based 
on their core β-lactam ring structure (Table 1). Penams are rings similar to that found in 
penicillin. Carbapenems are used to treat multidrug-resistant bacteria. Some commonly 
prescribed β-lactam antibiotics are ampicillin, amoxicillin, oxacillin, piperacillin, 
cefepime, ceftaroline, imipenem, and meropenem. Certain β-lactams bind to some PBPs 
stronger than others. For example, antibiotics with high affinity binding to PBP2 are 
ampicillin, cefaclor, cefotaxime, ceftizoxime, cefuroxime, cephalothin, cloxacillin, 
nafcillin, oxacillin, penicillin G, and piperacillin.(41-43) 
 
Table 1. Structure and classification of commonly used β-lactam antibiotics. 






















 Resistance to penicillin developed a few years after commercialization.(44) The 
first source of penicillin resistance was blaZ, which codes for a β-lactamase, a protein 
transcribed by the bacteria to degrade β-lactams.(44) β-lactamase enzymes are secreted 
by the bacteria to hydrolyze the β-lactam ring and thereby deactivate the antibiotic. β-
lactamase inhibitors, such as clavulanic acid, sulbactam, and tazobactam, were designed 
to inhibit the β-lactamase and prevent deactivation of the β-lactam antibiotic. Typically, 
β-lactam antibiotics are prescribed in combination with β-lactamase inhibitors. 
Additionally, some newer β-lactam antibiotics have been designed to be less susceptible 
to cleavage by β-lactamases. Today, about 90% of S. aureus strains are resistant to the 
original penicillin.(40) 
 Methicillin was introduced in 1959 to treat penicillin-resistant infections, but 
resistance to methicillin developed two years later.(45) Resistance to methicillin was 
not due to blaZ but caused by intrinsic resistance and alteration in PBPs.(46) All S. 
aureus strains have at least three PBPs that cross-link the cell wall. However, MRSA 
has an extra PBP, known as PBP2a, which has a low binding affinity for β-lactam 
antibiotics and thus allows for crosslinking in the presence of methicillin and other β-
lactam antibiotics. PBP2a is coded for by the mecA gene located on the Staphylococcal 
Chromosome Cassette mec (SCCmec). Specifically, PBP2a performs the transpeptidase 
activity of PBP2 in the presence of β-lactam antibiotics.(42) PBP4, which is not present 
in all S. aureus strains and not coded for by mecA, may also aid in β-lactam resistance 
due to its low affinity for β-lactam antibiotics.(47) Clinicians typically test for the 
presence of mecA to determine if the infecting microbe has methicillin-resistance. It is 
14 
unknown how S. aureus strains first obtained SCCmec, but the two active theories are 
that it was by bacteriophage-mediated transduction or through conjugation.(48) There 
are five different types of SCCmec, which vary in size and genetic composition. 
Genetic differences between the different SCCmec types do not play a role in resistance 
but are important for understanding the evolution of MRSA strains.(49) Methicillin is 
no longer used clinically because methicillin resistance is so widespread.  
 Hospital-acquired MRSA (HA-MRSA) was first found in hospital settings; 
however, community–acquired MRSA (CA-MRSA) became prevalent later. The 
classification of CA-MRSA versus HA-MRSA depends on the patient history; however, 
each type has distinct genotypic differences. CA-MRSA causes infections in healthy 
individuals who had not received hospital care prior to the onset of infection. HA-
MRSA generally infects individuals during hospitalization, typically within a 48-hour 
window.(18) HA-MRSA caused the majority of infections before the 1990s, whereas 
CA-MRSA became widespread in the late 1990s.(50) Community-acquired strains are 
considered to be more virulent than hospital-acquired strains.(51) The two most 
prevalent strains of MRSA, MRSA USA300 and MRSA MW2, are both community-
acquired. PVL, a pore-forming toxin, is not usually found in MSSA or HA-MRSA, but 
most CA-MRSA strains have the protein.(52) HA-MRSA tends to be more resistant to 
non-β-lactam antibiotics than CA-MRSA.(18) Thus, hospital- versus community-
acquisition provides a means of differentiating MRSA strains. 
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Drugs of Last Resort 
 Typically, β-lactam antibiotics are prescribed to initially treat Staph infections. 
However, if an infection does not clear up with β-lactams, a drug of last resort must be 
given. Although estimates in different countries vary, the World Health Organization 
estimates that approximately 44% of S. aureus infections are caused by MRSA.(12) 
First sold in 1954, vancomycin is the most commonly prescribed antibiotic to treat 
MRSA.(53, 54) Vancomycin, a glycopeptide, prevents cell wall crosslinking by binding 
to the D-ala D-ala moieties instead of binding to PBPs like β-lactams. Hearing loss, 
allergic reactions, and kidney damage has occurred with vancomycin usage.(55) In a 
hospital setting, vancomycin is considered to be the first-line therapeutic to treat 
MRSA. However, vancomycin cannot pass through the stomach lining, so it must be 
given intravenously to treat systemic infections. Additionally, vancomycin-resistant 
MRSA (VRSA) strains have been found due to the presence of the vanA gene, but 
VRSA is still rare.(56, 57)  
 Linezolid and daptomycin are other drugs of last resort used to treat MRSA 
infections. Linezolid, approved for commercial use in 2000, inhibits protein synthesis to 
prevent bacterial reproduction. Linezolid has oral bioavailability, is safe for short-term 
use, and can be inexpensive to manufacture. Although linezolid can be prescribed as an 
oral antibiotic, it is typically given intravenously to better control dosage and reduce 
medication administration errors. Daptomycin, approved by the FDA in 2003, inserts 
into bacterial cell membranes causing leakage of intracellular contents and cell death. 
Daptomycin is considered to be the second-line therapy for MRSA, while linezolid is 
the third-line therapy. Linezolid and daptomycin are referred to as “reserve antibiotics,” 
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meaning that they are only used in incidents where vancomycin or β-lactams cannot be 
used, allowing them to remain effective and prevent onset of resistance.(58) MRSA 
resistance to linezolid and daptomycin is rare but has been discovered.(59, 60)  
 Ceftaroline (FDA-approved in 2010) and telavancin (FDA-approved in 2009) 
have recently been approved for patient use in severe cases but must be administered 
intravenously.(54) Ceftaroline, also called Teflaro, is a β-lactam that has efficacy 
against MRSA. Ceftaroline is a prodrug, meaning it is prescribed in its inactive form 
and gets metabolized to the active form in the body. Although ceftaroline is a β-lactam 
antibiotic, the anti-MRSA property of the drug comes from its thiazole group rather 
than the β-lactam ring.(61) Telavancin, a synthetic derivative of vancomycin, works 
similarly to vancomycin in that it also disrupts bacterial membranes.(62) Since both of 
these antibiotics have been approved for human use within the last ten years, they are 
only used in rare instances where other antibiotics cannot be used or are not effective. 
 Other last-resort therapies to treat MRSA are tigecycline and 
quinupristin/dalfopristin. Tigecycline can be used to treat certain Gram-positive and 
Gram-negative bacteria by inhibiting protein synthesis.(63) Quinupristin/dalfopristin 
can be used to treat staph infections and vancomycin-resistant Enterococci infections. 
Quinupristin and dalfopristin work synergistically to inhibit protein synthesis.(64) Oral 
antibiotics are not often given to treat MRSA but some have been shown to be effective. 
Trimethoprim/sulfamethoxazole, a broad-spectrum antibiotic, synergistically inhibits 
folate synthesis, an important process for a variety of cellular components in the 
bacteria.(65) Trimethoprim/sulfamethoxazole is effective against approximately 80% of 
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MRSA infections.(66) These therapies are used rarely to treat MRSA infections and 
must be given intravenously. 
 Despite the number of FDA-approved drugs to treat MRSA infections, bacteria 
are very successful at mutating to create new resistance mechanisms. Resistance to 
vancomycin, coded for by the vanA gene, was discovered in 2002.(56, 57) MRSA 
infections that are resistant to daptomycin and linezolid have also been discovered but 
are currently rare.(59, 60) Today, there is no record of infections that are resistant to 
more than one drug of last resort. Although prudence when prescribing antibiotics has 
slowed down the evolution of antibiotic resistance, it is impossible to fully prevent 
antibiotic resistance from eventually occurring.  
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Chapter 2: 600-Da BPEI is a Non-Toxic Cationic Polymer 
Background 
 Our lab started working with branched polyethylenimine (BPEI), an 
inexpensive, cationic polymer, as a tool to prevent metal-binding in bacteria. Metals, 
such as calcium and magnesium, are necessary for a variety of functions in bacteria. 
Magnesium, for example, coordinates to negative charges on nucleotide phosphate 
groups, regulates DNA replication and transcription, and neutralizes cell 
membranes.(67) Calcium has been suggested to be important for bacteria motility, 
virulence, cell adhesion, pH homeostasis, quorum sensing, and spore formation.(68, 69) 
Although metal cations are important for a variety of functions, their transportation into 
the cytoplasm of the bacteria was not well understood. Porins transport the metals 
through the cell membrane, but our lab wanted to understand how these metals go 
through the cell wall of bacteria and what phenotypically happens to the bacteria when 
metal binding is blocked.(70) Bacillus subtilis 1A578 was used because it is a non-
pathogenic bacterium that is resistant to the antibiotic chloramphenicol, which allows 
for leniency in sterile techniques. Thomas found that BPEI caused the bacteria to form 
long, curling, filamentous bacteria instead of the normal, short, rod-shaped bacteria. 
Additionally, he found that the bacteria was unable to grow in chloramphenicol when 




Structure of BPEI 
 Polyethylenimines (PEI) are polymers with repeating amine groups separated by 
ethyl groups. Linear PEI (LPEI) contains only secondary amines that make the polymer 
a long chain. Branched PEI (BPEI) contains primary, secondary, and tertiary amine 
groups that make it is a very flexible polymer (Figure 3). The primary amines of BPEI 
are protonated at neutral pH, which contributes to the highly cationic nature of the 
polymer. Due to the presence of primary amines, BPEI has a higher charge density than 
LPEI. Because of the presence of a large number of primary amines and a high charge 
density, we investigated BPEI more thoroughly than LPEI.  
 
Figure 3. An example of one molecule of 600-Da BPEI is shown. 
 
 PEIs come in a range of sizes as small as 500-Da up to 1,000,000-Da and higher. 
BPEIs with molecular weights lower than 10-kDa have ratios of primary: secondary: 
primary amines of approximately one: two: one. BPEIs with molecular weights higher 
than 25,000-Da have ratios of amines that are closer to one another.(71) The repeating 
units of the polymers cause a distribution of sizes around an average MW. 
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Commercially-available low-MW BPEIs have larger size dispersity than the higher MW 
BPEIs.(72)  
   
Uses for BPEI 
 PEIs are used for a variety of industrial, environmental, and research purposes. 
PEI was used in the 1950s to improve paper’s wet strength to increase the paper’s 
ability to retain strength when saturated with water.(73) Additionally, PEIs have been 
used as a water treatment option because they are able to coagulate and flocculate a 
variety of contaminants.(74) PEIs have also been used in research laboratories for a 
variety of reasons. For instance, PEIs are used to flocculate contaminants to aid in 
purification of proteins.(75-77) Cell tissue culture can utilize PEI because the cationic 
charge attracts the overall negative charge of eukaryotic cells, causing them to attach to 
the plating surface.(78) BPEI, a commonly-used and heavily-researched polymer, can 
also be synthesized easily and inexpensively. 
 PEIs have been heavily researched as transfection agents for gene therapy. The 
positive charges of the PEI electrostatically interact with the negatively-charged 
phosphate groups of DNA, which condenses the DNA and allows for insertion into 
cells.(79, 80) PEIs are one of the most effective systems for gene transfer in mammalian 
cells. Higher-MW PEIs are more cytotoxic but also more efficient at transfecting.(81) 
For gene therapy, LPEI is typically a better transfecting agent than BPEI.(82, 83) Also, 
higher-MW LPEIs are more effective than lower-MW LPEIs.(79, 81) BPEI less than 
2,000-Da was unable to transfect eukaryotic cells.(84) Higher-MW PEIs are able to 
compact the DNA tighter and have a higher PEI:DNA complex surface charge, which 
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allows for easier insertion into eukaryotic cells.(79) The success with PEIs for gene 
therapy proves promising for other biological purposes.  
   Cationic polymers have antimicrobial properties, because they are able to 
interact with the negatively-charged cell wall of bacteria. The proposed mechanism by 
which they work is thought to be that they destabilize the cell wall and permeabilize the 
cytoplasmic and outer membranes.(72, 85) Many of these cationic polymers are used as 
biocides. However, to date, no cationic polymers have been approved for solution-based 
clinical treatment of microbial infections. Cationic polymers derived from polystyrene 
and poly(vinylpyridine) are the most commonly-researched polymers for antimicrobial 
activity.(85) Although BPEI has the highest charge density of the cationic polymers 
with antimicrobial activities, it has insufficient antimicrobial activity for clinical 
practices.(85) Modifications of BPEI have been made to increase the antimicrobial 
efficacy, typically by increasing the hydrophobic group to cationic moiety ratio.(86, 87) 




 Historically, many drug candidates have failed due to similar structural and 
chemical properties. Consequently, chemicals were determined to be “drug-like” if they 
fit a set of parameters denoted as the rule of five (RO5) concept.(88) The RO5 
determines the likelihood of a compound to be orally bioavailable and to have favorable 
pharmacokinetic characteristics. Approximately 90% of drug compounds in Phase II 
clinical trials or further fit with the RO5.(89) The RO5 states that drugs should have a 
22 
molecular weight lower than 500 g/mol, no more than 5 H-bond donors or 10 H-bond 
acceptors, and the computationally calculated Log P should be less than 5.(88) Of the 
RO5 parameters, molecular weight and lipophilicity have proven to be the most 
important.(90) The molecular weights of drugs in Phase I clinical trials are 
proportionally larger than the molecular weights of established drugs. The average 
molecular weight of drugs in clinical trials decreases as the trials progress. This is 
partially due to larger molecules having a higher probability of containing toxic 
moieties.(90) Lipophilic drugs are unlikely to advance far in clinical trials because they 
get metabolized faster, have low solubility, and have poor absorption.(90) Discovery 
and development of new antibiotics takes a minimum of 10 years to reach clinical trials. 
Thus, understanding a compound’s ability and probability of becoming a lead drug is 
important.  
 However, the RO5 does not pertain well to antibiotic discovery, but for largely 
unknown reasons.(91) Specifically, sulfa drugs are the only antibiotics that fall into the 
RO5.(91) Of the FDA-approved drugs, up to 95% of drugs are ionizable, and 67.5% are 
ionizable between pHs of 2 and 12 (75% weak bases, and 20% weak acids).(92, 93) The 
majority of basic drugs have pKas between 6.5 and 10.5.(93) Antibacterials (Gram-
positive and Gram-negative) are more hydrophilic and more polar compared to non-
antibiotic medicine.(91) The average molecular weight for Gram-positive targeting 
antibiotics is 813 g/mol, which is higher than the 600 g/mol cutoff of Gram-negative 
targeting antibiotics (average of 414 g/mol).(91) Natural product derivatives make up 
the majority of current antibiotics. However, natural product discovery has not been a 
focus of pharmaceutical companies recently because of the labor and funding required 
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to characterize and purify compounds , as well as the tendency to identify known 
compounds.(94) 
 Combination treatments are commonly used by clinicians to treat bacterial 
infections and are necessary to treat difficult infections. Combination therapies reduce 
the onset of resistance because bacteria have a harder time evolving when multiple 
targets are being inhibited.(13) Augmentin is one of the most prescribed drug 
combinations, consisting of the β-lactam amoxicillin and the β-lactamase inhibitor 
clavulanic acid. Previously, combination treatments were composed of existing 
antibiotics, but recent work has focused on designing new combinations with non-
established drugs. 
 
Purpose of Experiment 
 The purpose of the experiment was to determine the drug-like capabilities of 
BPEIs of varying molecular weights.  Cytotoxicity assays were performed on immortal 
human cells (Hela, HCT-166, and Hek-293) and on a primary kidney cell line (PCS-
400-010). Cytotoxicity assays showed that 600-Da BPEI was the least cytotoxic of the 
tested molecular weights. As molecular weight increased, toxicity increased. For this 




Preparation of Cationic Polymers 
 BPEI (600, 1200, 1800, and 10,000-Da) was purchased from Sigma-Aldrich. 
BPEI was easily dissolved in water. Due to BPEI’s stability, it can be stored in water for 
over one month without degradation. 
 
pH Titration of BPEIs 
 BPEIs were diluted with distilled water to 6 g/L concentration (0.01 M for 600-
Da BPEI). 50 mL of BPEI was titrated with 1.0 M HCl dropwise. The pH (measured on 
an Orion 3 Star pH meter) was recorded throughout. The titration curve was graphed. 
Data analysis was followed using the procedure outlined by Gibney et al.(72) In order 
to determine the pKas, the maximum buffer capacity for each pH range was determined. 
Buffer capacity is defined as the change in the amount of HCl added divided by the 
change in pH. Each titration was done twice and the data is presented as the average.  
 
Maintenance of Eukaryotic Cell Lines 
 Cell lines were purchased from ATCC and maintained by following company 
protocols. Hela (cervical cancer), HCT-116 (colon cancer), and HEK-293 (kidney 
cancer) cells were incubated at 37 °C, 5% CO2. Growth media was changed every three 
days. Cells were sub-cultivated when cell density reached 80% coverage to prevent the 
cell density from becoming too high. Sterile technique was used throughout. 
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CellTiter Viability Assay 
 A CellTiter-Blue (Promega) assay was performed as described by Burgett et 
al.(95) Briefly, cells were plated in 96-well culture plates and grown at 37 °C for 20-24 
hours. Compounds (dissolved in water) were delivered to the cells and grown for 
another 48 hours. Cell morphology and viability was qualitatively observed with a cell 
culture light microscope. CellTiter-Blue was added and allowed to react for one hour. 
Viable cells convert the resazurin dye in the assay to a fluorescent resorufin end 
product. Thus, the fluorescence signal detected is proportional to the number of viable 
cells. The fluorescence (544 nm excitation; 590 nm emission) was measured on a Tecan 
Infinite M20 plate reader. Growth relative to untreated cells was calculated. The 
required concentration to inhibit growth of 50% of the cells (IC50) was determined by 
graphing all concentrations versus relative growth and establishing the concentration 
where relative growth is 50%. All concentrations were done in triplicate.  
 
Nephrotoxicity Assay 
 A Pierce Lactate Dehydrogenase (LDH) Cytotoxicity (Thermo) assay was 
performed with PCS-400-010 cells. Cells were plated (2,500 cells/well) and grown for 
24 hours at 37 °C. The cells were treated and grown for another 24 hours. Supernatant 
(50 μL) was transferred to the reaction mixture (50 μL) for each well and the plates 
were incubated further at room temperature for 30 minutes. Stop solution (50 μL) was 
added to each well after 30 minutes. Absorbance was measured at 490 nm and 680 nm. 
To determine LDH activity, the 680 nm absorbance value was subtracted from the 490 
nm value. The percent cytotoxicity was calculated by subtracting the spontaneous LDH 
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activity from the treatment LDH activity and comparing to the maximum LDH activity. 
The study was done in triplicate. 
 
Results and Discussion 
Characterization of BPEI 
 Because BPEIs have primary, secondary, and tertiary amines, there should be 
three different pKas for BPEI. The majority of drugs are weak acids and bases, so 
understanding pKas is critical to understanding ionic forms throughout the body. The 
pKa of a drug affects pharmacokinetic characteristics, and establishing pKas are 
important for FDA regulation compliance.(93) The literature reports conflicting pKa 
values for BPEI. Therefore, the pKas for 600-Da, 1800-Da, and 10-kDa BPEIs were 
determined using potentiometric titrations with HCl. A titration curve of each BPEI 
shows a substantial buffering region around 7-9 pH for each polymer (Figure 4A). 
Another small shelf between 5-6 pH indicates another buffer region. In order to 
determine the pKa, the buffering capacity at each pH was determined by dividing the 
change in HCl added by the change in pH and plotting against the pH (Figure 4B). Then 
the pH of each buffer capacity peak was determined. The pKa1 for each BPEI was 
around 8.7 and pKa2 was around 5.1 (Table 2). The pKa of Tris base was determined to 
be 8.3 ± 0.1 which is less than 3% that of the accepted value of 8.1.(96) Each pKa 
determined was about 10% less than those determined by Gibney et al. using a similar 








Table 2. The pKa of BPEIs and Tris base. 
 pKas 
Experimental Literature 


















Tris Base 8.3±0.1 8.1
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600-Da BPEI has low cytotoxicity in vitro 
 A possible critique of utilizing BPEI in drug discovery is misunderstanding that 
cationic BPEIs are cytotoxic and thus unlikely to be useful as clinical antibacterial 
treatments. Reports show that cationic compounds, such as aminoglycosides and 
polymyxins, lead to nephrotoxicity.(97, 98) However, presumptions that all BPEIs are 
toxic overlook the stipulation that toxicity depends on molecular weight and 
concentration. High molecular weight BPEIs (over 25,000 Da) are cytotoxic, whereas 
the lower molecular weight BPEIs are non-toxic unless their concentrations are orders-
of-magnitude higher than the amount required for potentiation.(72, 99, 100) Low 
cytotoxicity was confirmed in our lab with in vitro cytotoxicity data using mouse 
fibroblasts,(3) human HeLa, human colon, and human kidney cell lines (Table 3). The 
IC50 values for 600-Da BPEI (100-1,000 μg/mL) are orders of magnitude higher than 
the amount required for potentiation (~1 μg/mL). An in vitro hemolysis assay, 
published by Gibney et al., showed that 600-Da BPEI had no hemolytic activity and 10-
kDa BPEI had minimal hemolysis (>5%) up to 2,000 μg/mL.(72) Drug-induced 
nephrotoxicity refers to irreversible kidney damage caused by a pharmaceutical. 
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Because of BPEI’s cationic nature, some may believe that the polymer could cause 
nephrotoxicity. An in vitro nephrotoxicity assay was performed using primary human 
renal proximal tubule epithelial cells (hRPTECs). The assay detects the release of the 
metabolic enzyme, lactate dehydrogenase (LDH). A lack of LDH release suggests that 
the membrane is not damaged and the test agent does not cause in vitro nephrotoxicity. 
Exposure to 600-Da BPEI caused minimal release of LDH (~1% at 8 μg/mL, 16 μg/mL, 
and 31 μg/mL; 3.5% at 62 μg/mL; and 8% at 125 μg/mL, Figure 5). As per the 
literature, these values are indicative of low toxicity.(101)  These values are much lower 
than the LDH release values for cationic and nephrotoxic, colistin (1% at 8 μg/mL; 
2.3% at 16 μg/mL; 18% at 31 μg/mL; 26% at 62 μg/mL; and 28% at 125 μg/mL, Figure 
5). The 1200-Da, 1800-Da, and 10-kDa BPEIs were more toxic than the 600-Da BPEI 
as seen with the CellTiter Blue cell viability (Table 3) and LDH assays (Figure 5). 
These data suggest 600-Da BPEI is preferred as a lead potentiator in drug discovery due 
to its low toxicity and low nephrotoxicity. 
 
Table 3. In vitro mammalian cytotoxic activity of BPEI 
Human Cell 
line 
Mean IC50 ± S.D. (μg/mL) 












691 ± 79 186 ± 28 59 ± 24 1.9 ± 0. 5 
Notes: Values are reported as the average of three trials ± standard deviation. Cells were 




Figure 5. 600-Da BPEI had minimal LDH release in a primary kidney proximal tubule 
cell line (PCS-400-010). The 1800-Da and 10-kDa BPEIs had higher LDH release than 
the nephrotoxic drug colistin. Error bars denote standard deviation (n=3). 
 
Conclusion 
 We found that lower molecular weight BPEI is less cytotoxic than higher 
molecular weight BPEI. While the IC50s of 600-Da BPEI was between 100-1,000 
μg/mL for each tested cell line, 10-kDa BPEI was more toxic with IC50s between 1-10 
μg/mL. The LDH cytotoxicity assay showed 600-Da BPEI had minimal LDH release. 
However, 1800-Da and 10-kDa released more LDH than the nephrotoxic drug colistin. 
Thus, we designated 600-Da to be the lead potentiator for future studies. The low 
toxicity of our lead potentiator is the result of its hydrophilic nature. 600-Da BPEI is 
very hydrophilic and completely miscible with water. Also, 600-Da BPEI molecules are 
very small and do not contain regions of hydrophobic character, as seen with cationic 
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peptides, aminoglycosides, and polymyxins. Thus, 600-Da BPEI lacks the energetic 
force that drives hydrophobic compounds into lipid membranes. Higher molecular 
weight BPEIs had higher toxicity and caused nephrotoxicity. BPEI ranging from 10,000 
– 1,000,000-Da possess less hydrophilic interiors that increase their lipophilicity and 
lead to membrane penetration and damage.  
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Chapter 3: Efficacy of β-lactam antibiotics against MRSA Restored 
Through Synergy with BPEI 
Background 
 Methicillin-resistant Staphylococcus aureus (MRSA) is a current and growing 
risk to human health. It causes serious infections that show remarkable resistance to 
antibiotic treatments. Originally acquired exclusively in healthcare settings, MRSA is 
now regularly found outside the healthcare environment.(102) Diagnosed or suspected 
MRSA infections require treatment with vancomycin, linezolid, or daptomycin.(54) 
Although resistance has developed to all three drugs of last resort, to date, no MRSA 
strain is resistant to more than one of them.(59, 103) Other drugs, such as ceftaroline 
and telavancin, have been approved for patient use in severe cases but must be given 
intravenously.(54) Yet, people suffer from MRSA infections because, MRSA is either 
misdiagnosed or not suspected, and ineffective first-line antibiotics, usually β-
lactams,(39) are given. After MRSA diagnosis, clinicians turn to drugs of last resort, but 
treatment delays can result in mortality or increased morbidity due to release of MRSA 
toxins into tissue.(103, 104) In 2011, MRSA infected 80,500 people; nearly 1 in 7 cases 
resulted in death (11,300; 14%).(1) Drug resistance hinders efforts to develop safe 
clinical treatments for MRSA infections. Fortunately, progress has been made towards 
developing new antibiotics such as oxadiazoles,(105) tedizolid,(106) and 
teixobactin.(107) The timing coincides with a critical period in antibiotic research and 
development, as MRSA is developing resistance to drugs of last resort, such as 
vancomycin.(57, 108, 109) Therapeutic approaches to overcome resistance factors 
include efflux-pump inhibitors that increase the intracellular concentration of 
33 
antibiotics.(110) Bacteria can also use β-lactamase enzymes to degrade the antibiotics; 
thus, treatment requires β-lactamase inhibitors. However, development of new 
antibiotics has slowed within the last 20 years, with the last new antibiotic class having 
been discovered over 30 years ago. 
 Little research has examined BPEI as an antibacterial agent. Of that which has 
been done, the majority has focused on BPEI used alone to combat Gram-negative 
infections. Wiegand et al. tested LPEI and BPEI against E. coli and found low efficacy, 
regardless of molecular weight.(100) In studies that looked at S. aureus, LPEIs had 
better activity than BPEIs but still had MICs of 30-40 μg/mL, with no effect caused by 
molecular weight.(100) Gibney et al. mirrored this observation and found that both 
LPEI and BPEI are selective against S. aureus over E. coli, because they gave lower 
MICs.(72) The MIC of BPEI was not dependent on the molecular weight and 
consistently had an MIC of around 100 μg/mL, which is too high to be considered 
effective for clinical purposes.(100) Previous research in the laboratory found that low-
MW BPEI prevented growth of chloramphenicol-resistant B. subtilis 1A578 in 
chloramphenicol.(70) This led to the idea that BPEI could potentially remove antibiotic 
resistance from pathogenic bacteria such as MRSA. 
 
Determination of Synergy 
 When developing new drug combinations, the drug interaction refers to the 
effect that the drugs have on one another. Synergy occurs when the drugs work together 
in order to increase the effectiveness. The opposite of synergy, antagonism, occurs 
when the effectiveness is reduced when the drugs are given together. Additivity occurs 
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when both drugs have an effect but are not increasing the efficacy of each other. 
Combination therapies of antibiotics are advantageous because they increase efficacy 
and reduce the onset of resistance.(13) Determination of synergy of antibiotic 
combinations is important for reducing dosage size, understanding drug mechanism, 
and obtaining novel patents.  
 A common technique for determining the in vitro level of synergy between 
drugs is a checkerboard assay. On a checkerboard assay, different combinations of 
antibiotics are added to 96-well plates. A consistent amount of bacteria is added to each 
well and allowed to grow for a certain amount of time. After, the fractional inhibitory 
concentration index (FICI) can be determined. For each antibiotic, the minimum 
inhibitory concentration (MIC) is the minimum concentration of one antibiotic required 
for the bacteria to not grow. For each well of bacteria that did not grow, an FICI is 
calculated using Equation 1 with the concentrations of each antibiotic in the specific 
well. An FICI less than 0.5 indicates synergy. An FICI greater than 1.0 indicates 
antagony. Between 0.5 and 1.0 indicates additivity. By determining the drug 
interactions of antibiotics using checkerboard assays, we can better understand the 






= FICA + FICB = FICI      (Equation 1) 
 
Purpose of Experiment 
 Although BPEI alone had impractically high MICs, it was hypothesized that 
BPEI would potentiate the activity of antibiotics against drug-resistant pathogens. Thus, 
the purpose of this experiment was to determine whether synergy was present between 
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BPEI and antibiotics against MRSA. We found that BPEI synergistically re-sensitized 
MRSA to β-lactam antibiotics. However, BPEI did not potentiate non-β-lactam 
antibiotics against MRSA. Additionally, the BPEI:β-lactam combination was effective 
for only MRSA and did not display synergy against MSSA, Escherichia coli, or 
Bacillus subtilis.  
 
Experimental Procedures 
Cell Lines Used 
 Bacterial cell lines were obtained from American Tissue Culture Collection: 
MRSA USA300 (ATCC BAA-1717™), MRSA 33592 (ATCC 33592™), MRSA 252 
(ATCC BAA-1720™), and Bacillus subtilis 6051 (ATCC 6051™). MRSA MW2 
(ATCC BAA-1707™) was a generous gift from Professor Suzanne Walker. MRSA 
700787 (ATCC 700787™), MSSA 25923 (ATCC 25923™), and Escherichia coli 
11775 (ATCC 11775™) were generous gifts from Professor Robert Cichewicz and 
Jarrod King. Clinical isolates were obtained from patient swabs at the University of 
Oklahoma Health Sciences Center and provided by Cindy McCloskey M.D. following 
institutional review board (IRB) approval. Table 4 lists bacteria strains used in the study 
and their characteristics. Since MRSA and MSSA are classified as biosafety level 2 
organisms (BSL-2), extra precautions were taken for all procedures. All studies were 




Table 4. Bacterial strains used in study. 




MRSA USA300 + 
Most commonly diagnosed strain of 
MRSA. 
Resistant to triple action antibiotic 
ointments.(111) 
MRSA MW2 + 
High rate of diagnosis. 
Particularly virulent strain. 
MRSA 700787 + Vancomycin-intermediate resistance. 
MRSA 33592 + Gentamicin-resistant. 
MRSA 252 + Hospital-acquired strain. 
MSSA 25923 + 
Methicillin-susceptible S. aureus 
strain. 
B. subtilis 6051 + Non-virulent reference bacillus strain. 
E. coli 11775 - Non-virulent Gram-negative strain. 
 
 
In Vitro Efficacy Checkerboard Assays 
 Checkerboard assays were used to determine synergy of BPEI with β-lactam 
antibiotics against bacteria. Stock solutions of oxacillin were made in DMSO and added 
to pre-sterilized 96-well plates with cation-adjusted Mueller-Hinton Broth so that the 
final DMSO concentration was <1%. Bacteria were added to each well on the plate so 
that the final cell density was ~5 x 10
5
 cells/mL. Optical density readings were made 
immediately after inoculation using a Tecan Infinite M20 plate reader with a 
wavelength of 600 nm. The plates were incubated for 20 hours in a humidified 
incubator at 35 °C and a final OD600 reading was recorded. The change in OD600 was 
calculated by subtracting the initial OD600 from the final OD600 reading. A change in 
OD600 greater than 0.050 was considered to be positive for growth. The minimum 
inhibitory concentration (MIC) was assigned as the lowest concentration of antibiotic or 
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BPEI that did not allow growth. The fractional inhibitory concentration index (FICI) 
was calculated using the previously-established equation.(112) An FICI lower than 0.5 
indicates synergy, between 0.5 and 1 represents additivity, and greater than 1 shows 
antagonism. Each assay was done as three separate trials and reported as the modal FICI 
value.  
 
Minimum Bactericidal Concentrations 
 Minimum bactericidal concentrations (MBC) were determined by counting 
colonies on agar plates inoculated with the contents of the 96-well plates after the final 
OD600 readings were taken. Specifically, 5 μL of cell suspension was transferred to a 
TSB agar plate for each well. The agar plates were grown for 24 hours at 35 °C. After 
growth, colony forming units were counted.  
 
Clinical Isolates of MRSA 
 The MIC of oxacillin and BPEI against 16 strains of MRSA and 5 strains of 
MSSA were determined using the Clinic Practice Guidelines.(54) The MIC of BPEI and 
oxacillin were determined by serially diluting each in 96-well plates with MHB. In 
separate wells, decreasing concentrations of BPEI were added to MHB with a constant 
amount of oxacillin (2 μg/mL). The same was done for decreasing concentrations of 
oxacillin with a constant amount of BPEI (4 μg/mL). Bacteria was added (5 x 10
5
 cells/ 
mL) to each well and grown until confluency at 35 °C. The OD600 was measured before 
and after growth. A change in OD600 greater than 0.05 was considered positive for 
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growth. Each MIC was determined in quadruplicate, and the values are presented as the 
average of four trials. 
 
Growth and Time-Killing Curves 
 TSB growth media augmented with various amount of BPEI and/or oxacillin 
was inoculated at 0.5% from an overnight culture of MRSA 700787. During cell growth 
at 35 °C, with shaking (200 rpm), the OD600 was monitored with a Jenway Genova 
UV/Visible Spectrophotometer hourly for each sample. Aliquots were taken at 0 hour, 4 
hours, 8 hours, and 24 hours. Each aliquot was serially diluted in fresh TSB and 
transferred to TSB agar plates. The agar plates were grown at 35 °C for 24 hours. After 
growth, colony forming units were counted. Each study was done in triplicate. 
 
Results and Discussion 
 Methicillin was initially introduced in 1959 to treat penicillin-resistant 
infections, but reports of methicillin-resistance began appearing just two years later.(45) 
Today, improved β-lactam antibiotics have clinically replaced methicillin. Some β-
lactams, such as oxacillin, ampicillin, and ceftizoxime are still used to treat Staph 
infections, but the increased prevalence of MRSA infections has made vancomycin a 
first-line antibiotic against septic S. aureus infections. Vancomycin is unable to cross 
the stomach lining and therefore must be given intravenously, which often requires 
hospitalization, can be symptomatic, and can cause complications such as hearing loss, 
allergic reaction, and kidney damage.(55) Furthermore, cases of vancomycin-resistant 
S. aureus (VRSA) have been found.(57, 108) Last-resort drugs such as daptomycin and 
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linezolid are effective against MRSA but are rarely prescribed in order to slow the onset 
of resistance. Thus, development of an orally-administered combination therapy that 
employs β-lactams could replace vancomycin as a first-line MRSA treatment. Because 
BPEI removed chloramphenicol resistance from B. subtilis 1A578 (chloramphenicol-
resistant strain), we hypothesized that BPEI could also remove MRSA’s resistance to 
ampicillin and other β-lactams. A quick screen (Figure 6) showed that BPEI is capable 
of reducing MRSA’s growth in ampicillin. 
 
Figure 6. In vitro assay of ampicillin against MRSA. When BPEI (2.7 µg/mL) is added, 
the MIC for ampicillin is between 12 and 25 µg/mL (checkered columns) while 
ampicillin without BPEI does not inhibit MRSA below 50 µg/mL concentration (solid 
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red columns). The growth of MRSA was evaluated by measuring the change in OD600 
after 20 hours. Cell growth in TSB without additives is denoted as Control.   
 
BPEI has synergy with β-lactam antibiotics against MRSA 
 Checkerboard assays were used to determine synergy between BPEI and β-
lactam antibiotics. Here we look at the two most common strains of CA-MRSA: 
USA300 and MW2. MRSA USA300 is the most common community-associated strain, 
which could be partially due to its low susceptibility to over-the-counter triple antibiotic 
ointments.(111, 113, 114) MRSA MW2 (also referred to as MRSA USA400) has 
additional toxins that make it particularly virulent. BPEI in combination with oxacillin 
showed synergy against multiple cell lines (Table 5). The BPEI:oxacillin combination 
against MRSA USA300 had a fractional inhibitory concentration index (FICI) of 0.266 
(Figure 7A). An FICI less than 0.5 indicates synergy, greater than 1.0 indicates 
antagony, and between 0.5 and 1.0 indicates additivity. MRSA MW2, had an FICI of 
0.250 for the BPEI:oxacillin combination (Figure 7B). BPEI (4 μg/mL) reduced the 
MIC of ceftizoxime from 256 μg/mL to 8 μg/mL against MRSA USA300 (FICI= 0.313; 
Figure 7C). Similarly, BPEI (8 μg/mL) reduced the MIC of ceftizoxime from 256 
μg/mL to 16 μg/mL against MRSA MW2 (FICI= 0.156; Figure 7D). Imipenem and 
BPEI exhibited synergy against both MRSA USA300 (FICI= 0.375; Figure 7E) and 
MRSA MW2 (FICI= 0.25; Figure 7F).  
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Figure 7. Checkerboard assays show synergy between BPEI and β-lactams on MRSA 
USA300 and MRSA MW2. BPEI had synergy with oxacillin (A, B), ceftizoxime (C, 
D), and imipenem (E, F) against MRSA USA300 (A, C, E) and MRSA MW2 (B, D, F). 
Each assay was performed as three separate trials, and the presented data is shown as 





Table 5. Minimum inhibitory concentrations and fractional inhibitory values of BPEI in 






MRSA 252 MRSA 33592 
MIC FICI MIC FICI MIC FICI MIC FICI 
BPEI 64 - 32 - 32 - 32 - 
Oxacillin 32 0.250 32 0.266 >256 0.501 256 0.281 
Ampicillin 128 0.188 2 0.516 256 0.375 256 0.516 
Amoxicillin 128 0.250 4 0.5 256 0.500 256 0.375 
Meropenem 2 0.313 4 0.250 32 0.504 8 0.563 
Ceftizoxime >256 0.156 256 0.313 >256 0.254 >256 0.5 
Piperacillin >256 0.266 16 0.313 >256 0.501 >256 0.501 
Cephalothin 4 0.5 2 0.5 32 0.281 32 0.375 
Imipenem 0.5 0.375 0.25 0.25 64 0.508 32 0.281 
Notes: MIC=minimum inhibitory concentration. FICI=fractional inhibitory 
concentration index. Each value is the average of three separate trials. 
 
 Two other commercially-available MRSA strains were also tested: MRSA 252 
and MRSA 33592. MRSA 252, a HA-MRSA strain, is one of the major strains found in 
the United Kingdom. Additionally, MRSA 252 is genetically diverse compared to other 
strains of MRSA.(115) MRSA 33592 (also denoted as MRSA 1063) is a CA-MRSA 
strain that also has resistance to gentamicin. Other β-lactam antibiotics such as 
amoxicillin, meropenem, and piperacillin had synergy with BPEI against MRSA MW2 
and USA300, but the synergistic effect was less prominent against MRSA 252 and 
MRSA 33592 (Table 5). MRSA 252, a HA-MRSA strain, only had synergy between 
BPEI and ampicillin (FICI=0.370; Figure 8A). BPEI had synergy with oxacillin 
(FICI=0.281; Figure 8B), amoxicillin (FICI=0.375), and cephalothin (FICI=0.375) 
against MRSA 33592. All other tested BPEI and β-lactam combinations had only 
additivity or no effect against MRSA 252 or MRSA 33592. 
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Figure 8. Checkerboard assays show synergy between BPEI and β-lactams on MRSA 
252 and MRSA 33592. BPEI had synergy with ampicillin against hospital-acquired 
MRSA 252 (A). BPEI had synergy with oxacillin against MRSA 33592 (B). Each assay 
was performed as three separate trials, and the presented data is shown as the average 
change in OD600. 
 
BPEI creates synergy with β-lactam antibiotics to stop VISA growth 
 Checkerboard assays demonstrate anti-MRSA properties of 600-Da BPEI mixed 
with β-lactam antibiotics (Table 6) against a MRSA strain containing PBP2a (ATCC 
700787™) that is also moderately resistant to vancomycin (vancomycin-intermediate S. 
aureus, VISA). BPEI has synergy (FICI<0.5) with oxacillin, ampicillin, amoxicillin, 
and meropenem (Figure 9A-C). Adding 600-Da BPEI (0.5 μg/mL) reduced the MIC of 
oxacillin from 64 μg/mL to 4 μg/mL against MRSA 700787. Increasing the 
concentration of 600-Da BPEI to 1 μg/mL resulted in a 128-fold decrease of the MIC of 
oxacillin to 0.5 μg/mL. Likewise, increasing the 600-Da BPEI concentration increases 
potentiation and decreases MIC values of amoxicillin, ampicillin, and meropenem. 
However, BPEI did not have synergy with methicillin; the FICI equals 0.563 which 




Figure 9. BPEI potentiates β-lactam activity against MRSA 700787. Checkerboard 
assays show that BPEI potentiates oxacillin (A), amoxicillin (B), and ampicillin (C) 
activity against MRSA 700787. Each assay was performed as three separate trials, and 
the presented data is shown as the average change in OD600. 
 




(μg/mL) FICI Outcome 





















Amoxicillin 128 8 4 1 0.313 Synergy 
Methicillin 64 4 4 2 0.563 Additivity 
Meropenem 2 0.5 4 0.5 0.375 Synergy 
Notes: MICA is minimum inhibitory concentration of the antibiotic; MICB is minimum 
inhibitory concentration of BPEI; FICI is fractional inhibitory concentration index. 
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BPEI potentiates oxacillin against clinical isolates of MRSA 
 We have been able to demonstrate synergy between BPEI and β-lactams against 
five commercially-available reference strains of MRSA. Since the long-term goal is for 
BPEI to be combined with β-lactams to treat clinical MRSA infections, clinical isolates 
of MRSA obtained from patients at the University of Oklahoma College of Medicine 
were tested. The laboratory of Cindy McCloskey M.D. confirmed that each isolate 
contained the mecA gene and therefore was resistant to oxacillin. The BPEI:oxacillin 
showed the best efficacy against the tested commercially-available MRSA panel, so this 
combination was used for further studies. We were motivated to see if the 
BPEI:oxacillin combination would be efficient against clinical isolates of MRSA. The 
MICs for oxacillin and BPEI separately were determined for each isolate. The minimum 
concentration of BPEI required to inhibit growth of the bacteria in the presence of 2 
μg/mL oxacillin (the breakpoint of susceptibility) was compared to the MIC of BPEI 
alone (Figure 10A, Table 7). In this test, eleven of the sixteen tested strains had an FICI 
less than 0.5. Additionally, the minimum concentration of oxacillin required to inhibit 
growth in the presence of 4 μg/mL BPEI was compared to the MIC of oxacillin alone 
(Figure 10B, Table 8). In this test, ten of the sixteen tested strains had an FICI less than 
0.5. Between the two tests, twelve strains showed synergy and the other four strains saw 
a reduction in MIC representative of additivity. This data demonstrates that 





Table 7. Treatment of clinical isolates of MRSA. Data shows the concentration of BPEI 















1 256 2 16 32 0.508 
2 8 2 1 32 0.281 
3 64 2 16 16 1.03 
4 64 2 8 32 0.281 
5 128 2 16 64 0.266 
6 32 2 8 64 0.188 
7 128 2 16 64 0.266 
8 256 2 8 8 1.01 
9 32 2 16 64 0.313 
10 16 2 32 256 0.25 
11 256 2 32 64 0.508 
12 64 2 32 128 0.281 
13 16 2 4 8 0.625 
14 32 2 8 64 0.188 
15 16 2 2 256 0.133 
16 32 2 2 256 0.125 
Notes: FICI is the fractional inhibitory concentration. MIC is the minimum inhibitory 














Table 8. Treatment of clinical isolates of MRSA. Data shows the concentration of 
oxacillin required to reduce the MIC of BPEI to 4 μg/mL. 
Strain # 
BPEI 




MIC      
(μg/mL) 





1 32 4 128 256 0.625 
2 32 4 2 8 0.375 
3 16 4 16 64 0.5 
4 32 4 8 64 0.25 
5 64 4 16 128 0.188 
6 64 4 0.5 64 0.078 
7 64 4 64 128 0.563 
8 8 4 64 256 0.75 
9 64 4 16 32 0.563 
10 256 4 4 16 0.266 
11 64 4 32 256 0.188 
12 128 4 8 64 0.156 
13 8 4 0.125 16 0.508 
14 64 4 4 32 0.188 
15 256 4 2 16 0.141 
16 256 4 8 32 0.266 
Notes: FICI is the fractional inhibitory concentration. MIC is the minimum inhibitory 
concentration. Each value is the average of four trials. 
 
 
Figure 10. BPEI and oxacillin together are effective at preventing growth of a clinical 
isolate of MRSA. The concentration of BPEI required to inhibit MRSA OU14 was 
reduced when simultaneously grown in 2 μg/mL oxacillin (A). Similarly, the 
concentration of oxacillin required to inhibit growth was reduced while simultaneously 
treated with 4 μg/mL of BPEI (B). The black line indicates the cutoff for growth at a 
change in OD600 of 0.05. Each data point is reported as the average of four trials. 
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Intermediate molecular weight BPEI has higher efficacy 
 BPEI is commercially available in a wide range of sizes (600 to 1,000,000-Da). 
We were motivated to determine whether increasing the molecular weight of BPEI 
increases its efficacy against MRSA 700787. The MICs of 1200-Da and 1800-Da BPEI 
alone (0.5 μg/mL) were lower compared to that of 600-Da BPEI alone (4 μg/mL; Figure 
11 A). The 1200 and 1800-Da BPEI had synergy with oxacillin (Figure 11B, C). Only 
0.125 μg/mL 1200-Da BPEI was required to reduce the MIC of oxacillin from 128 
μg/mL to 8 μg/mL against MRSA 700787. 10-kDa BPEI had an MIC of 4 μg/mL but 
did not demonstrate synergy with oxacillin (FICI= Figure 11D). Compared to the 600-
Da BPEI + β-lactam combination, the 1200-Da and 1800 Da + β-lactam combinations 
have superior in vitro efficacy. However, as shown previously, 600-Da BPEI shows 
negligible in vitro cytotoxicity against mammalian cells whereas toxicity increases for 
1200-Da, 1800-Da, and 10-kDa BPEI. Also, we did not anticipate LPEI would have 
activity; a short study confirmed this hypothesis. The 600-Da form of LPEI did not 
inhibit MRSA growth and did not potentiate ampicillin unless the concentration was 
high (54 μg/mL; Figure12). Because 600-Da BPEI was determined to be the lead 




Figure 11. Low and intermediate MW BPEI potentiate MRSA to oxacillin. 600-Da 
BPEI (A), 1200-Da BPEI (B) and 1800-Da BPEI (C) potentiate oxacillin acitivity 
against MRSA 700787 but 10-kDa BPEI (D) does not. Each assay was performed as 




Figure 12.  In vitro linear PEI assay against MRSA. LPEI alone does not affect the 
growth of MRSA through 54 µg/mL (striped red columns); addition of 9.3 µg/mL 
ampicillin provides some effect, though not enough to inhibit MRSA growth (thatched 
red columns). Growth of MRSA was evaluated by measuring the change in OD600 after 
20 hours. Cell growth in media (Control) or media with 1% DMSO show the increase in 
OD600 (solid red columns), while 50 µg/mL chloramphenicol serves as a negative 
control. 
 
BPEI:oxacillin combination is bactericidal 
 Monitoring the growth of MRSA 700787 reveals that bacteria exposed to sub-
inhibitory concentrations of BPEI and oxacillin fail to reach exponential phase when the 
two compounds are combined (Figure 13A). Aliquots were transferred to agar plates, 
and CFUs were counted from the 0 hour, 4 hour, 8 hour, and 24 hour time points to 
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determine if the lack of growth observed for the BPEI and oxacillin combination was 
bacteriostatic or bactericidal. After 8 hours, the control sample had the highest cell 
density (1 x 10
9
 cells/μL). The samples that contained BPEI or oxacillin had lower 
viable cell numbers in comparison to the control sample, but these values were still 
higher than the initial cell density (>1 x 10
5
 cells/μL). The viable cell count decreased 
for growth in both BPEI and oxacillin (47 CFUs/μL at 8 hours growth) and did not 
increase after 24 hours (Figure 13B). This data demonstrates that the mechanism by 
which BPEI and oxacillin prevents growth of MRSA is bactericidal.  
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Figure 13. 600-Da BPEI and oxacillin comprise a bactericidal combination in MRSA 
700787. Cells treated individually with BPEI or oxacillin were still able to grow but 
growth was inhibited when both BPEI and oxacillin were used (A). A time-kill curve 
shows that the combination has a bactericidal mechanism of action as seen with the 
drop in viable cell counts after 4 hours (B). Error bars denote standard deviation (n=3). 
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 To support this conclusion, minimum biocidal concentrations (MBCs) were 
determined from a checkerboard assay of MRSA containing BPEI and oxacillin. The 
MBC of BPEI was the same as the MIC (4 μg/mL) while the MBC for oxacillin was at 
least twice as large as the MIC (MIC= 64 μg/mL; MBC>128 μg/mL). The MBCs for 
the combination (1 μg/mL BPEI, 2 μg/mL oxacillin; Figure 14) were 2-fold greater than 
the combination’s MICs (1 μg/mL BPEI, 1 μg/mL oxacillin). If the MBC is less than 4-
fold the MIC, the drug is considered bactericidal and does not require the assistance of 
host defenses.(116) Since the MBC for BPEI and its oxacillin combination is not greater 




Figure 14. BPEI: oxacillin combination is bactericidal against MRSA. Dark shaded 
circles indicate wells where the bacteria grew as determined by an OD600 greater than 
0.05. Lighter shaded circles show where cells were not killed but did not reach an OD600 
of 0.05. Unshaded circles had less than 500 cells/μl. Bolded circles show an FIC less 
than 0.5. 
 
BPEI does not have synergy with other antibiotics 
 Since BPEI has synergy with most of the tested β-lactams antibiotics, non-β-
lactam antibiotics were also tested. Vancomycin, linezolid, and chloramphenicol each 
have different mechanism of actions. Vancomycin is a large a glycopeptide that targets 
cell wall synthesis. Linezolid, an oxazolidinone, inhibits protein synthesis and localizes 
intracellularly. Vancomycin and linezolid are prescribed to treat systemic MRSA 
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infections. Chloramphenicol inhibits protein synthesis but is not used to treat MRSA 
infections. Vancomycin, linezolid, and chloramphenicol did not yield significant MIC 
reductions in the presence of BPEI against any of the tested strains (Table 9). For both 
MRSA USA300 and MRSA MW2, the FICI for vancomycin and BPEI was 1.00 
(Figure 15A, B). Linezolid showed additivity with BPEI against MRSA USA300 
(FICI= 0.5; Figure 15C) and MRSA MW2 (FICI= 0.5; Figure 15D). Chloramphenicol 
was only tested against MRSA 700787 and only showed additivity with BPEI 
(FICI=0.5; Figure 15E). BPEI’s efficacy at potentiating antibiotics is specific to β-
lactam antibiotics which indicates that the mechanism of action involves PBPs. 
 
Table 9. Minimum inhibitory concentrations and fractional inhibitory values of BPEI in 













MIC FICI MIC FICI MIC FICI MIC FICI MIC FICI 
BPEI 64 - 32 - 32 - 32 - 4 - 
Vancomycin 1 1 1 1 1 1 2 0.5 2 1 
Linezolid 2 0.5 1 0.5 1 0.5 1 0.5 2 0.5 
Chloramph-
enicol 
- - - - - - - - 8 0.5 
Notes: MIC= minimum inhibitory concentration. FICI=fractional inhibitory 




Figure 15. BPEI does not potentiate synergy with vancomycin or linezolid.  
Checkerboard assays show that BPEI did not have synergy with vancomycin (A,B) or 
linezolid (C,D) against MRSA USA300 or MRSA MW2. Chloramphenicol and BPEI 
do not have synergy against MRSA 700787 (E). Each assay was performed as three 
separate trials, and the presented data is shown as the average change in OD600. 
 
BPEI:β-lactam efficacy is specific to MRSA 
 BPEI potentiation of β-lactam antibiotics is specific to MRSA. A methicillin-
susceptible S. aureus strain (MSSA 25923) was tested. BPEI only had modest additivity 
with oxacillin (FICI=0.750), ampicillin (FICI=0.750; Figure 16B), and amoxicillin 
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(FICI=0.750) against MSSA 25923 (Table 10). The different BPEI potentiation effects 
against MRSA versus MSSA support a mechanism involving PBP2a, which is present 
in MRSA but not in MSSA. We also report that the combination of BPEI and ampicillin 
does not have synergy against Gram-positive B. subtilis 6051 (FICI=1.0; Figure 16C) or 
Gram-negative E. coli 11775 (FICI=1.0; Figure 16D). These data lead us to believe that 
the mechanism by which BPEI potentiates β-lactams is specific for MRSA. 
 
Table 10. Lack of synergy of 600-Da BPEI and β-lactams against MSSA 25923. 
Strain Antibiotic 
MICA (μg/mL) MICB (μg/mL) 
FICI Outcome 
Alone Comb. Alone Comb. 
MSSA 
25923 
Oxacillin 0.064 0.032 32 8 0.75 Additivity 
Ampicillin 0.064 0.032 32 8 0.75 Additivity 
Amoxicillin 0.064 0.016 32 16 0.75 Additivity 
Notes: MICA is minimum inhibitory concentration of the antibiotic; MICB is minimum 




Figure 16. BPEI does not potentiates β-lactam activity against MSSA 25923, B. subtilis 
6051, or E. coli 11775. BPEI and ampicillin have synergy against MRSA MW2 (A). 
Checkerboard assays show that BPEI not potentiates ampicillin (B) activity against 
MSSA 25923. No synergy is seen between β-lactams and BPEI against B. subtilis 6051 
(C) or E. coli 11775 (D). Each assay was performed as three separate trials, and the 
presented data is shown as the average change in OD600. 
 
Conclusions 
 Rather than developing new inhibitors which require exhaustive clinical testing, 
we have discovered that some FDA-approved β-lactam antibiotics, such as oxacillin, 
can regain their efficacy against MRSA. The cost to the patient for treating Staph 
infections caused by MRSA is $695 to $29,000 more than treating MSSA infections.(6) 
The benefits to human health could be dramatic if the β-lactam + BPEI combination, 
used as a routine antibiotic therapy, can eliminate MSSA infections while 
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simultaneously preventing the growth of MRSA. Importantly, the data for S. aureus 
ATCC 25923 provide a potential route to treat, and prevent, antibiotic-resistant 
infections. By using a combination of BPEI and oxacillin to treat a non-resistant S. 
aureus infection, the emergence of β-lactam-resistant strains in vivo could be slowed. 
This benefit would not be possible with oxacillin alone. Currently, if a patient goes to 
the doctor with a Staph infection, the doctor will often prescribe antibiotics that are only 
effective if the infection is methicillin-susceptible. However, if the infectious agent is 
MRSA, the patient will have to undergo more vigorous treatments, such as 
intravenously antibiotics or amputation/ excision. Even still, one in seven patients 
infected with MRSA will end up dying from their infection.(1) Our proposal is that all 
patients with Staph infections will be prescribed BPEI in combination with a β-lactam 
(Figure 17). This would prevent the infection from getting worse in case the infectious 
agent is in fact MRSA; and therefore, increase the likelihood of success.  
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Figure 17. Proposed clinical application.  
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Chapter 4: Targeting Wall Teichoic Acid In Situ with Branched 
Polyethylenimine Potentiates β-Lactam Efficacy against MRSA 
Background 
 The ability of BPEI to potentiate β-lactams against MRSA shows an interesting 
way of disabling resistance. BPEI was only able to potentiate β-lactams and did not 
have synergy with any of the other antibiotic classes tested. Additionally, the BPEI: β-
lactam combination was only effective against MRSA which indicates a narrow-
spectrum mechanism of action. A new focus to antibiotic development has been for 
narrow-spectrum agents because more available targets exist compared to broad-
spectrum.(94) Thus, understanding the mechanism by which BPEI re-sensitizes MRSA 
to β-lactams would potentially open a new target and area for antibiotic development.  
The cell envelope of Gram-positive bacteria is composed of a membrane, 
peptidoglycan, and teichoic acids. Methicillin, a β-lactam antibiotic, occupies the active 
site of penicillin binding proteins (PBP) 1, 2, and 3 to prevent the enzymatic cell-wall 
synthesis function in S. aureus. In the presence of β-lactam antibiotics, MRSA performs 
cell-wall synthesis using PBP2a, a transpeptidase enzyme with very low affinity for β-
lactams. Hartman and Tomasz recognized and identified PBP2a in MRSA.(117) The β-
lactam/transpeptidase complex is stable; however, resistance arises because the rate of 
complex formation is much slower than the S. aureus cell division time. Thus, it is 
nearly impossible for the complex to form in vivo.(118) Fuda et al. also presented a 
structure of PBP2a with no realistic access to the active site, suggesting there had to be 
a conformational change that took place as a result of binding non-crosslinked 
peptidoglycan at a location other than the active site, setting the groundwork for future 
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allosteric regulation papers.(118) Nevertheless, the cell wall remains an especially rich 
antimicrobial target, containing many opportunities for disruption, such as 
peptidoglycan, teichoic acids,(41, 119) and novel proteins.(120) While these targets 
have shown promise, side-effects and slow progress towards clinical usage have 
hindered efforts to reduce the rate of MRSA infection and mortality.(121) While it is 
possible to stop teichoic acid expression in the cytoplasm, thereby disabling the 
function of PBP2a,(41) the quantity of drug required for activity prevented development 
into a clinical MRSA treatment.(121) 
 
Structure and Function of Teichoic Acids 
 Teichoic acids are anionic polymers that span the length of peptidoglycan in the 
cell walls of Gram-positive bacteria. Two types of teichoic acids exist: wall teichoic 
acid (WTA) and lipoteichoic acid (LTA). The teichoic acid portions of WTA and LTA 
have similar chemical structures, but they are linked to different cell regions. WTA 
covalently attaches to the NAM groups of peptidoglycan and extends to the 
extracellular space. LTA anchors to the lipid bilayer of the inner membrane with a 
linker and also extends to the extracellular space. Each teichoic acid consists of ribitol 
or glycerol phosphate groups and carbohydrates linked together with phosphodiester 
bonds (Figure 18). Diversity exists for the chemical structure of teichoic acids among 
bacterial species. Typically, S. aureus contains 1,5-D-ribitol-phosphates, but diversity 
can be seen even in the same strain.(122) B. subtilis WTA has a similar structure to that 
of S. aureus but has glycerol phosphates instead of ribitol phosphates and glycerol 
instead of N-acetylglucosamine. Gram-negative bacteria do not have teichoic acids. 
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Because of the large number of phosphate groups, teichoic acids provide an overall 
negative charge to the cell wall of bacteria. WTA constitutes up to 60% of the cell wall 
mass.(123, 124) Approximately one in nine peptidoglycan NAM units have WTA 
attached.(123, 125) Thus, WTA is an abundant and important component of the cell 
envelope. 
 
Figure 18. Structure of S. aureus teichoic acid (modified from Sewell and 
Brown).(126) R=H, D-ala, N-acetylglucosamine; n= 40 to 60 repeats. 
 
 Teichoic acids are known to be important for a variety of functions, including 
cell adhesion (127, 128) and biofilm production (128, 129) as well as host 
infection.(127, 130) However, their mechanisms are not well understood. Knockout 
strains of teichoic acid lost virulence and were unable to colonize in vivo.(127, 131) 
Gene knockout studies have shown that WTA mutants have clumping morphologies 
and reduced septa formations.(132) Lipoteichoic acid (LTA)-deficient mutants, 
conversely, have a drastically elongated morphology.(133) Additionally, WTA and 
LTA impart an overall negative charge to the cell wall, attracting metal cations.(134-
136) Teichoic acids have proven essential for cell wall protein localization. Specifically, 
WTA is necessary for localization and activation of cell wall machinery, such as 
penicillin binding proteins (PBPs) and autolysins.(123, 137, 138) Inhibition of WTA 
synthesis led to improper localization of PBP2a/4, making MRSA susceptible to β-
lactams.(41, 139) Although previously thought to be necessary, WTA is not essential to 
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viability but may be involved in β-lactam resistance.(132, 140) Atilano et al. found that 
WTA helps guide PBP4 to the division septum, which agrees with the knowledge that 
WTA mutants have decreased levels of crosslinking.(137) However, Gautam et al. 
contend that crosslinking in S. aureus occurs at both the division septum and the 
peripheral cell wall after division.(141) WTA was reported to be involved in bringing 
the autolysin Atl to the division septum.(142) FmtA, a protein upregulated in S. aureus 
in the presence of cell wall inhibitors, also lost septal localization in WTA knockout 
strains.(138)  Preventing WTA synthesis or effectively preventing proper WTA 
function is a potentially viable area of antibiotic discovery. Thus, we were motivated by 
the connection between WTA deletion and cell wall morphology to disable WTA with a 
chemical agent that binds WTA in an electrostatic manner. 
 
Principles of NMR, Confocal Microscopy and Fluorescently Labelled Proteins. 
Principles of Nuclear Magnetic Resonance 
 Nuclear magnetic resonance (NMR) spectroscopy is a commonly used technique 
that can determine the structure and physical properties of organic and inorganic 
compounds. Magnetic fields around nuclei of atoms produce radio waves that can be 
detected with the instrument. Only nuclei with a spin can be detected in NMR 
spectroscopy; thus, not all nuclei are considered NMR active.  Some commonly-used 








P. For NMR spectroscopy, the sample is 
placed inside a large magnet, which applies a constant magnetic field throughout the 
sample. After the sample is excited with a radio pulse, the weak signal is measured with 
radio receivers. A Fourier transform converts information from the time-domain to the 
65 
frequency domain. The magnetic moment of a nuclei is proportional to the spin of the 
nuclei and depends on the energy difference between the two spin states of the nuclei. 
However, differences in the electric environment lead to shifts in the frequency of the 
signals because the electrons around the nucleus oppose the applied magnetic field. 
Shielding occurs when the nucleus feels a weaker magnetic field due to an increased 
electron density around the nucleus. De-shielding occurs when the nucleus feels a 
stronger magnetic field because the electron density around the nucleus has been 
reduced. Differences in shielding versus de-shielding are often caused by neighboring 
atoms. Thus, the chemical shifts provide information about the chemical structure of the 
compound. 
 1D-NMR spectroscopy only provides information about one type of nuclei as 
frequency versus intensity. 2D-NMR spectroscopy plots two frequency axes which can 
relate adjacent atoms. 2D-NMR is helpful in understanding more complicated 
structures. Many types of 2D-NMR experiments exist. One of the most common types 
of 2D-NMR, also discussed in this dissertation, is heteronuclear multiple-bond 
correlation spectroscopy (HMBC). HMBC examines correlations between different 
nuclei (heteronuclear) over longer ranges (2-4 bonds). Other common methods are 
correlation spectroscopy (COSY) which looks at the same nuclei (homonuclear) 
correlations from adjacent atoms, total correlation spectroscopy (TOCSY) which looks 
at homonuclear correlations from longer ranges, or heteronuclear single-quantum 
correlation spectroscopy (HSQC) which looks at heteronuclear correlations of adjacent 
atoms. The intensity of these spectra are typically shown using a third-dimension and 
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displayed as contours. Ultimately, 1D- and 2D-NMR are valuable tools to better 
understand chemical structures, physical parameters, and molecular interactions.  
 
Principles of Laser Scanning Confocal Microscopy 
 Light microscopy suffers from limitations in resolution at high magnifications 
because of diffraction rings. This phenomenon, called diffraction-limited resolution, 
equals the wavelength of light divided by two times the numerical aperture of the 
microscope. Resolution refers to the minimum distance between two objects that can be 
distinguished as separate points. The best resolution that can be obtained on a light 
microscope is approximately 200 nm. However, normal light microscopes rarely reach 
that limit because of a large depth of focus and lens aberrations.  
 Laser scanning confocal microscopy (LSCM), a high resolution fluorescence 
microscopy technique (Figure 19), can reach diffraction-limited resolution. For LSCM, 
a laser is scanned onto a specimen by the scanning unit. The laser excites a fluorophore 
on the sample which then emits a lower energy photon. A dichromatic mirror removes 
excitation rays and allows emitted rays through to the detector. The emitted ray then 
focuses through a pinhole aperture that removes any out of focus rays and prevents 
them from reaching the detector. The pinhole aperture allows for the microscope to 
view optical sections and overcomes limitation issues caused by a large depth of focus. 
The detector measures the number of photons from each spot of the imaging plane 
which creates a pixel. Then, each pixel is reconstructed to create the final image. LSCM 
makes it possible to reach diffraction-limited resolution limits and allows for imaging of 
interior cell components.  
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Figure 19. Diagram of a simplified LSCM. 
 
 Fluorescence occurs when a substance absorbs light radiation and emits that 
light as a form of luminescence. Typically, the emitted fluorescence has a longer 
wavelength and lower energy than the excitation radiation. A Jablonski diagram can be 
used to visualize this phenomenon (Figure 20). An electron in the ground state (S0) 
absorbs a photon which excites that electron to an excited state (S1). The excited 
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electron undergoes vibrational relaxation to the lowest vibrational level causing the 
electron to lose a small amount of energy. After, fluorescence occurs when the electron 
goes from the excited state to the ground state; in which, a photon of lower energy is 
released. The difference in wavelength between the excitation wavelength and the 
emission wavelength is known as the Stokes shift. For confocal microscopy, a 
fluorescent compound is excited with a laser beam.  
 
Figure 20. A Jablonski diagram showing the different energy levels that are 
encountered in fluorescence.  
 
Principles of Fluorescence Labels 
 Fluorescent probes or dyes are commonly used for biological imaging. For 
fluorescent labelling, a specific protein, biomolecule, or functional group is tagged with 
a fluorophore. The fluorophore selectively binds to an area of concern and emits a 
fluorescence signal when excited by light of a certain wavelength. Each probe has a 
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different excitation wavelength spectrum and emission wavelength spectrum which 
allows for imaging of multiple probes in the same cell. Fluorescent labels can be either 
small fluorescent probes such as DAPI or fluorescent proteins such as green fluorescent 
protein (GFP). With the use of fluorescent dyes, we are able to accurately track the 
location of different biological components.  
 Small molecule fluorescent probes (typically 20-100 atoms), also called 
fluorophores, contain several π-bonds which allow for emission of light when excited 
with a light source. The π-system of the fluorophore is capable of absorbing photons of 
a certain wavelength range which excites an electron to an excited state. These probes 
usually have conjugated doubled bonds or aromatic groups which create an electronic 
environment favorable for fluorescence. Environmental factors such as pH, solvent, and 
chemical environment can affect the properties of the probe. Quantum yield refers to the 
efficiency of the number of emitted photons per absorbed photon. Each probe has a 
unique molar absorption coefficient which references how strongly the probe holds the 
light. Another important characteristic is the lifetime, the time required for an excited 
electron to return to the ground state. Photobleaching is another characteristic to 
consider which refers to loss of fluorescence upon continuous excitation.  
 The first fluorescent protein discovered, GFP, was discovered in the sea pansy in 
the early 1960s by Osamu Shimomura.(143) Since then, many GFP-derivatives have 
been made that excite and emit at different wavelengths, have increased stability, and 
can serve different functions. Most of the fluorescently labelled proteins have a beta 
barrel structure that creates a cylinder shape that protects the inner sidechains. The 
inward-facing sidechains of the barrel induces fluorescence in the protein and affect the 
70 
color of the chromophore because they create a hydrogen-bonding network and 
electron-stacking interaction. Fluorescent proteins tag other proteins or areas of interest 
without compromising the function of either protein. A large advantage of fluorescent 
proteins is that they can be introduced into the genome of bacteria which then allows for 
consistent expression after multiple growth cycles.  
 For this study, many different fluorescent probes were used. DAPI was used as a 
DNA stain to distinguish the cell wall from the cytoplasmic space. DAPI binds to A-T 
regions of DNA found in the cytoplasmic region. It has an excitation maximum 
wavelength of 358 nm and an emission wavelength of 461 nm. Another stain used was 
Alexa Fluor 488, a dye from the Alexa Fluor family of dyes. Alexa Fluor 488 was 
tagged to BPEI in order to track BPEI’s localization in the cell. It has a maximum 
excitation of 495 nm and an emission wavelength of 519 nm. Fluorescent proteins were 
tagged to specific proteins in the cells. Green fluorescent protein (GFP), tagged to 
PBP2, has an excitation of 395 nm and an emission of 509 nm. Yellow fluorescent 
protein (YFP), tagged to PBP4, has an excitation peak of 514 nm and an emission peak 
of 527 nm. Each of these probes served specific purposes in order to determine the 
mechanism of action of the BPEI: β-lactam combination. 
 
Purpose of Experiment 
 The continued emergence of resistance could be stemmed by re-sensitizing 
resistant strains of S. aureus to currently ineffective antibiotics, such as the β-lactam 
oxacillin. This approach will be viable only if the expression and/or functionality of 
proteins that contribute to resistance, such as PBP2a, are inhibited. PBPs are 
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indispensable for cell growth as they create essential crosslinks between adjacent 
peptidoglycan segments. Targeting PBP2a with inhibitors has been shown to re-
sensitize resistant strains to methicillin.(144) In contrast, BPEI may indirectly disable 
PBP2a as evidenced by our discovery that BPEI administered in concert with β-lactams, 
makes MRSA susceptible to the antibiotics. The purpose of these experiments was to 
determine the mechanism by which BPEI potentiates β-lactam antibiotic activity against 
MRSA. Laser scanning confocal microscopy (LSCM) images show that BPEI binds to 
the cell wall where it can interrupt the function of teichoic acids, inactivate PBP2a, and 
restore β-lactam activity. NMR spectroscopy data demonstrate that BPEI binds to 
WTA, an anionic polymer found in MRSA cell walls, likely via electrostatic attraction 
between the cationic polymer and the anionic teichoic acid. Checkerboard assays using 
BPEI and β-lactams indicate that synergy is not present on a WTA-deficient mutant. 
Thus, WTA is necessary for BPEI’s synergistic effect with β-lactams against MRSA. 
WTA is important for localization of MRSA’s resistance factors, PBP2a and 
PBP4.(137, 145) LSCM of fluorescently-labelled proteins show that BPEI delocalized 
PBP4 from the division septa. Thus, the proposed mechanism behind BPEI’s synergistic 
properties with β-lactam antibiotics is that the polymer indirectly disables PBP2a and 





Synthesis of the BPEI:Dye Conjugate 
 Low-molecular weight BPEI (Sigma-Aldrich) was added to Alexa Fluor 488 dye 
provided in the Alexa Fluor 488 Protein Labeling Kit (Life Technologies) at a ratio of 
200 µL BPEI (3 mg/mL stock in Milli-Q H2O) per tube of powdered dye. After 
allowing the dye and BPEI to form the conjugate over 1.5 h at 25 °C, the product was 
stored at 4 °C and used without further purification. Images of unconjugated Alexa 
Fluor 488 and unconjugated BPEI were imaged to confirm that localization patterns 
were created by the BPEI:Alexa Fluor 488.  
 
Labeling Cells with the BPEI:Dye Conjugate 
 Cultures of E. coli 11775, B. subtilis 6051 and MRSA 700787 at mid-log growth 
phase were pelleted by centrifugation at 2,000x g for 5 minutes, and the growth media 
supernatant was removed. 6 µM DAPI in phosphate-buffered saline (1X PBS, pH 7.2) 
was added to re-suspend the cell pellet, which was allowed to incubate for 5 minutes at 
room temperature. The BPEI-dye conjugate was then added to a final concentration of 
100 μg/mL. Two control samples were prepared with either unconjugated BPEI or 
Alexa Fluor 488 alone and added to MRSA cells as described above. The stained 
bacterial cells were immediately fixed by resuspension with 4% paraformaldehyde 
(PFA) followed by a 10-fold dilution in 1X PBS. Cells were added to a microscope 
slide immediately prior to imaging. 
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Confocal Microscopy and Image Processing 
 PFA-fixed cells were mounted in 1X PBS and imaged using a Leica SP8 LSCM 
with a 63x/1.4NA oil objective. A 405 nm GaN diode laser line was used to image 
DAPI, and a 488 nm argon laser line was used to observe Alexa Fluor 488 fluorescence. 
Single optical sections were acquired of cells that had adhered to the coverslip, for 
highest axial resolution, with a pixel resolution of 80 nm × 80 nm. Instrument settings 
were kept fixed for all imaging to allow for direct comparison of fluorescence intensity. 
 To visualize the relative localization of fluorescence, independent of intensity, 
images were processed (ImageJ v1.49m) such that the total fluorescence intensity 
within each image was visible. To determine the relative fluorescence intensity between 
images, the fluorescence intensity of both the DAPI and the Alexa Fluor 488 were 
normalized to the respective intensities in the MRSA sample treated with BPEI 
conjugated with Alexa Fluor 488. 
 
WTA Purification 
 The NMR experiments require 10–20 mg WTA isolated from 2-4 liters of 
bacterial cell culture. The poly(ribitol phosphate) WTA used in this work was isolated 
from B. subtilis W23(146, 147) (B. subtilis (Ehrenberg) Cohn ATCC 23059) rather than 
from MRSA, allowing high volumes of culture to be processed with minimal risk to 
personnel. This also allows us to take the sample into the NMR facility room, which is 
not rated for BSL-2 work. In the rare instance of sample breakage, using WTA from B. 
subtilis W23 does not present a clean-up hazard nor require decontamination of the 
expensive NMR analysis probes, magnets or spectrometers. 
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 B. subtilis W23 cells were grown in LB media to an OD600 reading of 
approximately 0.8. After growth, the cells were harvested by centrifugation and 
physically disrupted using an Avestin® EmulsiFlex-C3 homogenizer. The insoluble cell 
wall was collected, placed in boiling 6% (w/v) SDS for 1 hour, washed with sterile 
water and EDTA then placed in 10% trichloroacetic acid (TCA) and treated for 48 
hours at 4 °C. After allowing the TCA to remove the bound WTA from the cell wall, 
the WTA was collected in the supernatant and placed into a 500-Da molecular weight 
cutoff dialysis membrane. Membrane dialysis was performed at 4 °C in 1.5 L of sterile 
water with continual water changes over a 48-hour period. The final 4 hours of dialysis 
took place in a 1-kDa molecular weight cutoff membrane to assure sample purity. The 
sample was lyophilized and kept at -20 °C until use. 
 
NMR Spectroscopy 
 NMR samples were prepared in Eppendorf tubes by mixing purified WTA with 
low-MW BPEI in D2O. The pH was measured with a microscopic pH probe and adjusted 
to 7.2 if necessary. A 3-mm NMR tube was filled with 160 L of a 2 mM sample of 
WTA, BPEI, or a combination of 2 mM BPEI with 2 mM WTA in D2O. All NMR 
experiments were performed in 3-mm tubes using 28 shims Agilent VNMRS-500 MHz 
equipped with a triple-resonance PFG probe. Pulse sequences for each experiment were 
supplied by Agilent. Data acquisition and processing were completed using VNMRJ 
2.2C software on the Red Hat Linux 4.03 operating system. After processing, all 
experiments were analyzed using Sparky software. The NMR spectra were collected at 
277K and referenced internally to the water signal at its correlating temperature.  
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Checkerboard Assay of WTA-Deficient Cells 
 MRSA MW2 and MRSA MW2 ΔtarO (referenced in Campbell et al., 
2001)(145) were a generous gift from Professor Suzanne Walker. Checkerboard assays 
were used to determine synergy of BPEI with β-lactam antibiotics against bacteria. 
Stock solutions of antibiotics were made in DMSO and added to pre-sterilized 96-well 
plates with cation-adjusted Mueller-Hinton Broth so that the final DMSO concentration 
was <1%. Bacteria were added to each well on the plate so that the final cell density 
was ~5 x 10
5
 cells/mL. Optical density readings were made immediately after 
inoculation using a Tecan Infinite M20 plate reader with a wavelength of 600 nm. The 
plates were incubated for 20 hours in a humidified incubator at 35 °C and a final OD600 
reading was recorded. The change in OD600 was calculated by subtracting the initial 
OD600 from the final OD600 reading. A change in OD600 greater than 0.050 was 
considered to be positive for growth. The minimum inhibitory concentration (MIC) was 
assigned as the lowest concentration of antibiotic or BPEI that did not allow growth. 
The fractional inhibitory concentration index (FICI) was calculated using the 
previously-established equation.(112) An FICI lower than 0.5 indicates synergy, 
between 0.5 and 1 represents additivity, and greater than 1 shows antagonism. Each 
assay was done in triplicate and reported as the modal FICI value.  
 
Imaging of Fluorescently Labeled Proteins 
 MRSA COL strains with green fluorescent protein (GFP)-labelled PBP2 or 
yellow fluorescent proteins (YFP)-labelled PBP4 were a generous gift from Professor 
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Mariana Gomes de Pinho. Bacteria were inoculated 0.5% into TSB media from an 
overnight culture. Some samples were grown in 64 μg/mL BPEI. The cells were grown 
to mid-log phase at 37 °C (OD600=0.5). After growth, the cells were centrifuged, and the 
supernatant was removed. The cells were stained with DAPI to differentiate the 
cytoplasm. The cells were centrifuged and supernatant was removed. After the samples 
were fixed with 4% paraformaldehyde for 10 minutes, the paraformaldehyde was 
removed and the samples were mounted in 1x PBS. Samples were imaged using a Leica 
SP8 LSCM (Leica, Buffalo Grove, IL, USA) with a x64/1.4 numerical aperture oil 
objective. A 405 nm GaN diode laser line was used to image DAPI and a 488 nm argon 
laser line was used to observe GFP and YFP fluorescence. Single optical sections were 
acquired from cells that had adhered to the coverslip with a pixel resolution of 30 nm. 
Instrument settings were constant for all imaging to allow for direct comparison. Images 
were processed with ImageJ so that the fluorescence intensity for each signal was 
visible. Quantitative analysis of each image was done, and ANOVA was used to 
establish statistical significance.   
 
Results and Discussion 
BPEI localizes on the cell wall of Gram-positive bacteria 
 Based off the efficacy data in Chapter 3, we anticipate that BPEI re-sensitizes 
MRSA to β-lactam antibiotics by interacting with teichoic acids. If true, BPEI’s 
interaction with MRSA should be confined to the cell wall. By conjugating BPEI to a 
fluorescent marker, Alexa Fluor 488, we were able to visualize BPEI localization in 
bacterial cultures using LSCM. Individual transverse optical sections clearly show BPEI 
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interaction with the MRSA 700787 cell wall region (Figure 21A). Using DAPI, a DNA-
binding fluorescent dye, as a marker for the cytoplasm within the cells (Figure 21B), the 
merged image (Figure 21C) confirms that BPEI was not detected within the cytoplasm, 
verifying that BPEI does not traverse the lipid bilayer membrane. BPEI: Alexa-Fluor 
488 similarly bound to the perimeter of B. subtilis 6051 cells (Figure 21D-E). Control 
images of B. subtilis cells (Figure 22) show that the signal was not caused by 
unconjugated Alexa Fluor 488 or auto-fluorescence. B. subtilis and MRSA are both 
Gram-positive bacteria with similar cell wall structures.  
 
Figure 21. Optical sections of BPEI binding to MRSA and B. subtilis. MRSA, stained 
with BPEI: Alexa Fluor 488 (A) and DAPI (B), is imaged by LSCM. The merged image 
(C) shows BPEI binding to the cell surface but not within the cytoplasm. Similarly, B. 
subtilis stained with BPEI: Alexa Fluor 488 (D) and DAPI (E), and the merged image 
(F), shows a high affinity between BPEI and B. subtilis.  Scale bars equal 5 µm. 
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Figure 22. Alexa Fluor 488 signal was caused by conjugated BPEI. Images shown are 
B. subtilis cells treated with BPEI:Alexa Fluor 488 (top row), unconjugated Alexa Fluor 
488 (middle row), or unconjugated BPEI (bottom row). The left column shows the 
detected Alexa Fluor 488 signal. The middle column shows the detected DAPI signal. 
The right column shows the merged images with both signals. Each image shows raw 
intensity. Scale bars equal 5 μm. 
 
 Optical sections of E. coli cells treated with BPEI: Alexa-Fluor 488 revealed 
minimal fluorescence intensity within the cell envelope, indicating a weaker interaction 
between the E. coli cell envelope and BPEI (Figures 23). This may explain the absence 
of antibiotic potentiation against E. coli in our study (Figure 16D). The absolute 
intensity shows non-specific interaction (Figure 23A-C). When the fluorescence signal 
intensity is normalized to the MRSA signal, no Alexa Fluor 488 signal is detected 
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(Figure 23D-E). E. coli, a Gram-negative bacteria, has an outer cell membrane that may 
prevent BPEI from getting to the cell wall to localize. Also, Gram-negative bacteria do 
not have teichoic acids. 
 
Figure 23. Optical sections of BPEI binding to E. coli 11775. E. coli stained with 
BPEI-Alexa Fluor 488 (A) and DAPI (B), is imaged by LSCM and the absolute 
fluorescence intensity is shown. The merged image (C) shows non-specific localization 
of BPEI. BPEI is not seen when normalized to the fluorescence intensity of BPEI on B. 
subtilis (D-F).  Scale bars equal 5 µm. 
  
The microscopy data, showing BPEI located in the cell wall region and not the 
cytoplasm, suggests that the observed antibiotic potentiation against MRSA is caused 
by an interaction of BPEI with some component of the bacterial cell wall. One major 
component of the Gram-positive cell wall is teichoic acid, a phosphodiester polymer 
whose anionic phosphate groups have been shown to interact strongly with metal 
cations.(134-136) BPEI, with its polycationic properties, has the potential for very 
strong electrostatic interactions with the polyanionic WTA molecules. This interaction 
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would involve the primary amines of BPEI and the phosphate groups of WTA (Figure 
24). This interaction can be observed using nuclear magnetic resonance (NMR) studies 
of mixed BPEI-teichoic acid solutions and compared to NMR spectra of pure teichoic 
acid. 
 
Figure 24. The cationic amine groups of BPEI electrostatically bind to the anionic 
phosphate groups of WTA. 
 
BPEI electrostatically binds to WTA 
The 1-D 
31
P spectra (Figures 25A, B) show significant changes after mixing 
WTA with low-MW BPEI. WTA is a phosphodiester polymer with a heterogeneous 
arrangement of N-acetylglucosamine (NAG), D-alanine, and hydroxyl groups. This 
creates variations in conformation of the poly(ribitol) backbone and differences in the 
phosphate conformations that generate distinct 
31
P NMR peaks. In the presence of low-
MW BPEI, the 
31
P NMR peak at 1.3 ppm is very intense, demonstrating that a large 
fraction of the phosphates have similar conformations. However, signals near 4 ppm are 
produced by phosphates in a de-shielded environment. The downfield shift arises from a 
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loss of electron density around the phosphorous nucleus, an effect that could be caused 
by a hydrogen bond between the phosphate oxygen and a BPEI amine group. The 





(heteronuclear multiple bond coupling) NMR data (Figure 26A, B). This experiment 




P nuclei. For flexible 
molecules, internal motion and dynamics causes relaxation of NMR signals;(148, 149) 




P HMBC signals are difficult to observe. When molecular motion is 
restricted, the signals are stronger. Phosphate:amine binding from the WTA:BPEI 
interactions likely occurs through electrostatic attraction between the numerous cationic 
primary amines of BPEI and anionic phosphate groups of WTA (Figure 24). Low 
molecular weight quaternary ammonium compounds have recently been shown to 
overcome resistance if the number of cationic sites is increased.(150) Therefore, the 
optimal cationic amine polymer should have a high number of primary amines while 





P NMR spectra of WTA before (A) and after the addition of low-MW BPEI 





Figure 26. Spectral changes are also manifested in the heteronuclear multiple-bond 
correlation (HMBC) spectra when comparing pure WTA (A) and WTA with BPEI (B). 
The P-31 signals near 4 ppm are correlated with the proton signals of NAG sugar 
groups. However, clear identification of specific interactions is prevented by the 




 Because low-MW BPEI binds to WTA, the cationic polymer has the ability to 
change WTA properties by altering molecular structure and/or creating steric bulk from 
the branched polymer. This would change or prevent the interaction of WTA with 
PBP2a and thus disable the enzyme. The same effect can be created through WTA-
deficient strains of MRSA, which are re-sensitized to amoxicillin, ampicillin, 
methicillin, nafcillin, and ceftizoxime.(41) An inhibitor of WTA synthesis, tunicamycin, 
re-sensitizes MRSA to β-lactams such as methicillin, oxacillin, cefotaxime, and several 
others.(145) Inhibition of another regulatory gene, tarG, also re-sensitizes MRSA 
strains to traditional β-lactams(132, 140, 151) like imipenem.(119) Thus WTA, while 
not essential to viability,(132, 140, 151) is involved in β-lactam resistance.(152) WTA 
helps to optimally localize PBP2a, and WTA-deficient mutants show a decreased 
functionality of the protein.(41) It additionally localizes PBP4, which is essential for the 
highly cross-linked peptidoglycan exhibited by MRSA and for the expression of β-
lactam resistance in CA-MRSA strains.(137) Thus, restoration of β-lactam activity in 
therapeutic clinical usage could be achieved with antibiotics or other compounds that 
target WTA synthesis or interrupt the ability of WTA to localize PBP2a in the proper 
configuration required for peptidoglycan crosslinking. If this perspective is true, there 
should be little or no benefit when BPEI and β-lactam antibiotics are used to treat non-
resistant S. aureus (MSSA) strains that do not express PBP2a. BPEI and β-lactam 
antibiotics did not have synergy against non-MRSA strains such as MSSA, B. subtilis 
6051, and E. coli 11775. Also, BPEI did not provide a benefit for potentiating non-β-
lactam antibiotics.  
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WTA is important for BPEI potentiation of β-lactam antibiotics 
 We hypothesized that BPEI potentiation of β-lactam antibiotics requires WTA. 
Studies have shown that WTA is important for β-lactam resistance in MRSA and aids 
with the localization of PBP4 to the division septum.(41, 145, 153, 154) WTA is 
dispensable for cell growth; however, WTA-deficient mutants of MRSA have an 
increased susceptibility to β-lactam antibiotics.(145) Also, inhibiting WTA synthesis by 
chemical inhibition of TarO, the protein responsible for the first step of WTA synthesis, 
results in a decreased resistance.(145) Recent work focused on development of new 
WTA inhibitors to fight MRSA with reduced protein binding effects.(154-156) 
Removal of WTA through genetic or chemical means reduced CFUs in mice treated 
with imipenem.(153) Disabling mature WTA in the cell wall should have a similar 
effect. 
 The cationic amines of BPEI electrostatically interact with the phosphate groups 
of WTA, sterically hindering the WTA and cell wall. Thus, we wanted to evaluate the 
requirement of WTA for synergy seen between oxacillin and BPEI against MRSA. 
MRSA MW2 ΔtarO, a WTA-deficient mutant, was used for this purpose.(145) For 
wild-type MRSA MW2, oxacillin and BPEI had synergy (FICI= 0.250; Figure 27A). 
The MIC of oxacillin was 64-fold lower against MRSA MW2 ΔtarO (0.5 μg/mL) in 
comparison to the wild-type MRSA MW2 (32 μg/mL), which supports the premise that 
WTA is important for β-lactam resistance in MRSA. For MRSA MW2 ΔtarO, the MIC 
of oxacillin only dropped 2-fold so that the FICI of the BPEI:oxacillin combination was 
0.531, indicating additivity instead of synergy (Figure 27B) Also, a checkerboard assay 
was performed using sub-lethal tunicamycin, a drug found to inhibit WTA 
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synthesis.(145) Although tunicamycin is a good potentiator of β-lactams against MRSA, 
it cannot be used clinically because of severe neurological toxicity.(157, 158) 
Tunicamycin decreased the MIC of oxacillin to 0.250 μg/mL (128-fold) against wild-
type MRSA MW2 (Figure 27D). Adding tunicamycin to the checkerboard assay of 
oxacillin and BPEI removed synergy against MRSA MW2 (Figure 27C). Both of the 
assays for MRSA MW2 ΔtarO and MRSA MW2 with tunicamycin showed no synergy 
between oxacillin and BPEI, which tells us that WTA is essential for the synergistic 
mechanism of BPEI and oxacillin. The combination of BPEI and ampicillin was also 
tested against MRSA MW2 and MRSA MW2 ΔtarO. BPEI and ampicillin have 
synergy against MRSA MW2 (FICI= 0.188; Figure 28A). However, BPEI did not 
exhibit synergy with ampicillin against MRSA MW2 ΔtarO (FICI= 0.500; Figure 28B). 
These data suggest that the synergistic effects seen between BPEI and β-lactam 




Figure 27. Mechanism by which BPEI makes MRSA susceptible to oxacillin is through 
WTA. BPEI and oxacillin have synergy against MRSA MW2 (A). Synergy is lost 
against MRSA MW2 ΔtarO (B) and MRSA MW2 with sub-lethal tunicamycin (0.250 
μg/mL; C). Tunicamycin potentiates oxacillin against MRSA MW2 (D). Each assay 
was performed as three separate trials, and the presented data is shown as the average 




Figure 28. WTA is required for synergy between ampicillin and 600-Da BPEI. BPEI 
and ampicillin are synergistic (FIC=0.188) on the wild-type MRSA MW2 (A). MRSA 
cells lacking WTA through deletion of tarO (B) do not have synergy (FIC=0.5). Each 
assay was performed as three separate trials, and the presented data is shown as the 
average change in OD600. 
 
BPEI prevents proper localization of cell wall machinery 
 BPEI localizes in the cell wall of Gram-positive bacteria (including MRSA) 
where it electrostatically binds to WTA. We hypothesize that in situ binding of BPEI to 
WTA would delocalize PBP4 and PBP2a to prevent proper function of MRSA’s 
resistance factors. Although all S. aureus strains have three PBPs that crosslink the cell 
wall (PBP1, PBP2, and PBP3), some MRSA strains also have PBP4 which aids in 
resistance for CA-MRSA.(47) WTA not only localizes PBP4 but also appears to be 
important for PBP2a, as indicated by the fact that genetic modification and chemical 
inhibition of WTA synthesis causes MRSA to become re-sensitized to β-lactams.(137, 
145, 159) This led to the hypothesis that BPEI sterically hinders WTA, thereby 
preventing proper localization of PBP2a and PBP4. This in situ binding of WTA with 
BPEI has not been investigated previously, though chemical inhibition of WTA 
synthesis has been shown to work in combination with β-lactam antibiotics to kill 
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MRSA.(145, 153-156, 159) MRSA COL strains with GFP-labelled PBP2 or YFP-
labelled PBP4 were obtained from Professor Mariana Gomes de Pinho. PBP4:YFP 
normally localizes at the division septum of dividing cells. However, PBP4:YFP 
delocalizes throughout the entire cell wall when WTA synthesis is prevented.(137) 
PBP2:GFP delocalizes when FtsZ (membrane-associated filaments that form the Z-ring 
of cell division) is altered. PBP delocalization of MRSA COL PBP2:GFP (strain 
referenced in Tan et al.)(160) and MRSA COL PBP4:YFP (strain reference in Atilano 
et al.)(137) by BPEI was tested. Because BPEI electrostatically binds to WTA, we 
expected BPEI to prevent proper localization of PBP4:YFP but to not necessarily alter 
localization patterns of PBP2:GFP.  
 A WTA-deficient mutant had a decreased level of peptidoglycan cross-linking, 
which Atilano et al. proposed was due to delocalization of PBP4.(137) Further analysis 
showed that TagO (the protein responsible for WTA synthesis) localizes at the division 
septum prior to PBP4, which suggests a direct protein-protein interaction.(137) Atilano 
et al. found that WTA knockout mutants with a defective TagO protein led to PBP4 
delocalization throughout the cell wall during division.(137) This result was confirmed 
using a different probe by Gautam et al.(141) Atilano et al. found a direct interaction 
between the amount of WTA present (not just the TarO protein) and the amount of 
PBP4 recruited to the division septum.(137) Using the same MRSA COL PBP4:YFP as 
was used by Atilano et al., we found that BPEI similarly prevents proper localization of 
PBP4 to the division septum (Figure 29). We found that calculating the fluorescence 
content of the septa versus the non-septa area of the cell wall showed that the proportion 
of fluorescence intensity in the septa is higher for untreated cells (62 ± 18 %) versus 
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treated cells (47 ± 18 %). Imaging showed no qualitative difference of septal 
fluorescence proportion between untreated and treated cells for the PBP2:GFP (Figure 
30). Other PBPs, such as PBP1 and PBP2, did not have abnormal localization in the 
ΔtarO mutant.(137) PBP2a fluorescently labelled proteins have yet to be reported, but 
we hypothesize that a similar localization pattern would be seen for PBP2a. MRSA 
loses resistance to β-lactam antibiotics when treated with WTA synthesis inhibitors 
such as targosil, ticlopidine, and tunicamycin.(41, 139, 153) PBP2a interactions with 
WTA were determined using SDS-PAGE experiments.(138) Thus, it has been 
suggested that WTA is important for recruitment of PBP2a to the division septum.  
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Figure 29. LSCM of MRSA Col PBP4:YFP shows that PBP4 primarily localizes at the 
division septum of dividing cells (A, B). BPEI delocalizes the PBP4 from the division 
92 
septum (C, D). Quantitative analysis of the fluorescence intensity at the division septum 
(S) versus fluorescence intensity at non-septum regions (L) was performed for untreated 
and BPEI-treated samples. Analysis was done for 100 cells of each sample that shows a 
visible closed septum. The PBP4 for untreated cells (S/L= 0.62 ± 0.18) localized 
heavier at the division than the BPEI-treated samples (S/L= 0.47 ± 0.18). p-values < 
0.0001. Scale bars equal 2 μm. 
 
 
Figure 30. LSCM of MRSA PBP2:GFP shows that PBP2 primarily localizes at the 
division septum of dividing cells. BPEI does not appear to delocalize PBP2. Scale bars 
equal 2 μm. 
 
Conclusions 
 We have shown here that BPEI localizes on the cell wall of Gram-positive 
bacteria but not Gram-negative bacteria. Specifically, BPEI electrostatically binds the 
WTA of MRSA and B. subtilis. For MRSA, WTA is necessary for localizing cell wall 
machinery. Thus, by inhibiting WTA function in situ, MRSA loses resistance to β-
lactams through delocalization of PBP4 and PBP2a. 
 Since the golden age of antibiotic development, very few new classes of 
antibiotics have been discovered. Here, we have found a novel mechanism to target 
MRSA. By blocking the PBP2a and PBP4 resistance pathways with BPEI, β-lactam 
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antibiotics were able to kill MRSA. Previous research focused on inhibition of WTA 
synthesis to prevent PBP2a/4 function.(41, 139, 161) Here, we have described a 
different approach that, in our opinion, departs from the status quo by deactivating 
mature WTA within the cell wall through electrostatic interactions with BPEI. Non-
toxic 600-Da BPEI was able to potentiate β-lactam efficacy against MRSA. The 
mechanism of action involves BPEI electrostatically binding to WTA and thereby 
preventing WTA from properly localizing PBP2a/PBP4 (Figure 31). The importance of 
this discovery is finding a new target for MRSA drug development. Although we 
envision improving human health with β-lactam plus polymer combinations, this 
represents a new pathway to develop other antibiotic treatments. Disabling PBP2a with 
cationic polymers enables advancement of antibiotic drug discovery by providing ways 
for other researchers to reinvigorate antibiotic development efforts that have stalled in 




Figure 31. Our proposed mechanism of action is that BPEI electrostatically binds to 
WTA, which creates steric hindrance and prevents proper localization of PBP2a. 
Therefore, BPEI disables PBP2a through delocalization, and β-lactam antibiotics 




Chapter 5: Morphological Examination of the Effect of BPEI on 
MRSA 
Background 
 BPEI electrostatically binds to WTA in the MRSA cell wall which creates steric 
hindrance and prevents proper function of WTA. WTA is required for proper 
localization of cell wall machinery. Of importance for MRSA’s resistance to β-lactam 
antibiotics, WTA is required for proper localization of PBP4 (137, 141) and has been 
suggested to be important for localization of PBP2a.(41, 137) WTA-deficient cells were 
unable to localize PBP4 to the division septum of actively dividing cells and lost 
resistance to β-lactam antibiotics.(41, 137) We were able to replicate these results using 
BPEI to inhibit mature WTA through in situ binding. Additionally, WTA is important 
for localization and function of Atl, the main autolysin in MRSA,(142) and FmtA, 
another resistance factor in MRSA.(138) Atl localizes at the division septum of dividing 
cells, similar to PBP4 and PBP2.(142) However, Schlag et al. found that Atl distributes 
evenly over the cell wall of WTA-deficient mutants.(142) FmtA is upregulated in the 
presence of β-lactam antibiotics.(162) Qamar and Golemi-Kotra found that FmtA binds 
to WTA and has a conformational change when bound.(138) FmtA localizes at the 
division septum of actively dividing cells. However, WTA-deficient mutants of S. 
aureus showed FmtA localization to be scattered all over the cell wall.(138) FmtA is 
suggested to be a penicillin-binding protein with cross-linking abilities similar to PBP2 
and PBP4.(138, 162) Thus, the importance of WTA for localization and function of 
numerous cell wall proteins indicates that removal or inhibition of WTA would cause 
drastic morphological changes.  
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 Multiple studies have confirmed that WTA is important for morphology of 
Gram-positive bacteria. Since WTA and LTA are structurally similar, we also anticipate 
that BPEI interacts with the phosphate groups of LTA, which is also important for 
morphology. SEM images of S. aureus showed an increased cell diameter and rougher 
cell surface when WTA synthesis is prevented.(142) Genetic removal of WTA results in 
severe aberrations in cell septa, cell wall flaking, and altered morphologies.(139, 142) 
Similar effects are seen with chemical inhibition of WTA.(139, 163) Removal of LTA 
through genetic mutation caused morphological defects in S. aureus such as multiple 
septa formation, thickened wall envelope, and unrounded shapes.(164, 165) Richter et 
al. found a small molecule that inhibits LTA synthesis and causes an increase in cell 
size, cell surface deformities, and thicker cell wall envelope.(166) WTA is also 
important for morphology of B. subtilis cells. WTA-deficient B. subtilis cells have an 
enlarged rounded shape instead of the typical short rod-shape.(132, 167) LTA-deficient 
B. subtilis cells have smaller diameters, abnormal septa formation, and cell 
bending.(133) Thus, teichoic acids are important for bacterial cell morphology. 
 
Principle of Electron Microscopy 
 The first electron microscope was invented in 1931 by Hans Busch. Since then, 
numerous modifications have made electron microscopy one of the most commonly 
utilized scientific instruments today. Electron microscopy utilizes the principle of 
Abbe’s equation which states that the maximum resolution that can be obtained is 
diffraction limited by the size of a particle’s wavelength. For light microscopy, the best 
possible resolution is proportional to the wavelength of the light and inversely 
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proportional to the numerical aperture. Thus, the absolute best resolution that can be 
obtained is approximately 200 nm. However, electrons have much smaller wavelengths 
than photons which results in resolution limits around 50 pm at best. For an electron 
microscope, Abbe’s equation states that the maximum resolution is inversely 
proportional to the accelerating voltage of the electron beam. Same as light microscopy, 
resolution for electron microscopes is typically limited by aberrations.  
 Electron microscopy utilizes many similar principles to light microscopy. 
However, the use of electrons instead of photons requires special modifications. An 
electron gun, often made of tungsten, generates a beam of electron.  In order to maintain 
a coherent beam, the microscope system is kept under high vacuum (less than 10
-6
 
mbar). Instead of glass lens, electromagnetic lens are used to focus and disperse the 
electron beam through the column of the microscope. In order to view images generated 
by an electron microscope, special detectors, cameras, or viewing screens are used.  
 Scanning electron microscopy (SEM) scans electrons on the surface of a 
specimen. The produced signal then reconstructs the topography of the specimen 
(Figure 32). SEM uses a relatively low accelerating voltage (5-30 kV) to prevent full 
penetration of the electron beam through the sample. The electron gun, vacuum system, 
and lenses are similar for all electron microscopes. The lenses in SEM work to focus the 
final ray into a fine point. For SEM, a scanning coil scans the electron beam along the 
imaging plane. Each signal from the detector represents a pixel in the final image. 
Commonly used SEM detectors detect either secondary electrons or backscattered 
electrons.  Secondary electrons are low energy electrons that are ejected from the 
specimen by inelastic scattering with the electron beam. An Everhart-Thornley detector 
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detects the secondary electrons by attracting them to the biased grid with a low voltage. 
The brightness of the signal is dependent on the number of electrons that reach the 
detector. Everhart-Thornley detectors are placed at an angle to the sample which gives 
the resulting image a 3-dimensional appearance. Backscattered electrons are high 
energy electrons that elastically scatter when the electron beam interacts with the 
specimen. A backscattered detector is placed directly above the sample. At best, SEM is 
able to reach resolution limits around 1-10 nm. 
 Transmission electron microscopy (TEM) transmits a beam of electrons through 
a sample, and an image forms based off the interaction with the sample (Figure 32). 
TEM uses a higher accelerating voltage (greater than 100 kV) in order to fully penetrate 
through the sample. Samples for TEM must be thin enough to allow for full electron 
transmission. The lenses for TEM create a coherent electron beam. The electron waves 
that penetrate through the specimen directly form the image. Since some of the 
electrons interact with the sample, contrast is seen between differences in electron 
densities. Phosphor screens or TEM cameras record and display the final image. At 
best, TEM is able to reach resolution limits around 50 pm. 
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Figure 32. Simplified diagrams of an SEM (left) and TEM (right). 
 
 Contrast is found in electron microscopy based off how much the electron beam 
interacts with the sample. Organic materials do not provide sufficient interaction to be 
imaged on an electron microscope. Thus, imaging of biological samples typically 
requires heavy metal staining to increase contrast of the sample. Higher molecular 
weight metals have better stain efficiency. Thus, the most commonly used TEM stains 
contain lead or uranium because of their high molecular weights and small grain sizes. 
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For SEM, sputter coating minimizes charging and increases contrast for imaging. 
Sputter coating deposits a thin layer of conductive material, most commonly gold 
palladium or iridium, on the sample. Uncoated biological material will cause charging 
from the electrical current on the sample and severely hinder the image quality. 
 Besides staining of samples, other techniques are required to prepare a sample 
for electron microscopy. First, the samples must be fixed to stop all biological processes 
and preserve the sample. Commonly used fixatives for bacteria are formaldehyde, 
glutaraldehyde, and osmium tetroxide (also used as a stain). Water cannot be placed in a 
conventional electron microscope. Thus, ethanol or acetone are used to dehydrate the 
bacteria. The cells must also be dried prior to imaging. For SEM, use of a critical point 
dryer or a drying agent such as hexamethyldisilazane (HMDS) prior to sputter coating 
prevents the bacteria from being crushed. For TEM, instead of drying the cells, the cells 
are placed in an embedding medium which replaces any liquid in and around the 
bacteria with a plastic resin. Then, an ultramicrotome cuts the resin-embedded bacteria 
to a thickness less than 100 nm. The thin sections are placed on copper grids to be 
imaged in a TEM.  
 
Purpose of Experiment 
 We examined morphological abnormalities to MRSA and B. subtilis cells 
caused by BPEI. Specifically, we found that BPEI caused B. subtilis cells to become 
elongated and twisting as opposed to their normal short, rod-shaped morphology. 
Similarly, MRSA cells had difficulty dividing, increased in size, and displayed cell wall 
degradation when treated with BPEI. Also, an autolysis assay showed that BPEI 
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prevents autolysis in MRSA. Thus, inhibiting the function of mature WTA using BPEI 
negatively impacts cell division and alters morphology. Ultimately, the purpose of the 
experiment was to determine whether electrostatic binding of WTA would cause 
morphology alterations similar to those seen when WTA synthesis is inhibited 
genetically or chemically. 
 
Experimental Procedures 
Phase Contrast Imaging 
 Bacillus subtilis 6051 cells were inoculated in LB growth media 1% from an 
overnight inoculation. Cells were grown at 37 °C with shaking in either the presence or 
absence of 130 μg/ml BPEI. At OD600 readings of approximately (± 10%) 0.2, 0.5, and 
1.0, the cell morphology was observed using an Olympus BX50 phase contrast 
microscope with a 100X / 1.30 NA oil immersion objective. The procedure was 
replicated to confirm results. 
 
Scanning Electron Microscopy 
 Bacteria cells were inoculated 0.5% from an overnight culture and grown at 37 
°C with shaking (with or without BPEI). The optical density was monitored, and growth 
was stopped when the bacteria reached late-lag phase. Aliquots were fixed with a 
mixture of 2% glutaraldehyde and 2% formaldehyde in 0.1 M cacodylate buffer for 30 
minutes at room temperature. The cells were washed and fixed with 1% OsO4 for 30 
minutes at room temperature in the dark. Afterwards, the cells were washed three times 
with water. One drop of each sample was placed on poly-L-lysine coated coverslips. 
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The samples immediately underwent a dehydration series by immersion in ethanol 
solutions (20%, 35%, 50%, 70%, 95%, and 100%) for 15 minutes each. The samples 
were dried with HMDS and then sputter-coated with AuPd. The samples were imaged 
on a Zeiss NEON SEM. Size analysis was performed on ImageJ, and ANOVA was used 
to establish statistical significance. 
 
Autolysis Assay 
 The autolysis protocol used was modified from Mani et al.(168) MRSA 700787 
cells were inoculated 0.5% from an overnight culture in TSB (some with the addition of 
BPEI) and grown to an OD600 of approximately 0.450. The cells were pelleted and 
washed once with cold water. The cells were then resuspended in 0.05 M Tris-HCl (pH 
of 7.5) with 0.05% Triton X-100, and incubated at 30 °C without shaking. The OD600 
was monitored every 20 minutes with a single flip of the cuvette. The percentage drop 
in OD600 was calculated for each measurement. The study was done in triplicate, and 
values are reported as the average with standard deviation. 
 
Transmission Electron Microscopy  
 Preparation for TEM was modified from Campbell et al.(139) Cells were grown 
in TSB media (some with BPEI) at 37 °C with shaking from a 0.5% overnight 
inoculation for 2 hours (late-lag phase). The samples were spun down and fixed with 
2.5% glutaraldehyde, 2% formaldehyde in 0.1 M cacodylate buffer for 2 hours at room 
temperature and then washed three times with cacodylate buffer. The cells were stained 
with 1% OsO4 in 1.5% PFA for 2 hours at room temperature in the dark and washed 
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three times with water. The samples were stained with 1% uranyl acetate for 30 minutes 
at room temperature in the dark and washed three times with water. A dehydration 
series with ethanol (50%, 70%, 95%, 95%, and 100%) was done for 20 minutes each. 
The samples were placed in propylene oxide (PO) for 1 hour with one change of solvent 
at the 30 minute mark. The cells were infiltrated with freshly made Epon in increasing 
increments of Epon:PO (1:2, 1:1, 2:1) for 1 to 2 hours each. The samples were then 
placed in 100% Epon and left overnight at room temperature. The cells were transferred 
to fresh Epon and allowed to sink to the bottom of an embedding mold. The samples 
were embedded for 24 hours at 60 °C. An ultramicrotome with a glass knife was used to 
thin-section the blocks to 90 nm thickness. Sections were placed on 200-mesh copper 
grids. The grids were stained for 30 minutes with 1% uranyl acetate. Imaging was done 
on a JEOL 2000-FX TEM at 200 kV accelerating voltage. 
 
Results and Discussion 
BPEI alters the cell morphology of Bacillus subtilis cells 
 Deleting WTA/LTA synthesis genes leads to abnormal cell shape and length 
because the absence of teichoic acids disrupts the proper function of cell wall enzymes. 
These morphology changes can be duplicated in situ by exposing B. subtilis cells to 
BPEI. Abnormal morphology was observed for B. subtilis 6051 cells grown in sub-
lethal BPEI. B. subtilis cells grown in sub-lethal BPEI had an elongated, curling 
morphology (Figure 33D-E) that was most prominent during late lag phase (~0.2 
OD600). At mid-log phase (~0.5 OD600), the morphological difference is less prominent. 
After stationary phase (~1.0 OD600) was reached, the difference between treated and 
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untreated cells was unnoticeable. Cells grown under normal conditions remained rod-
shaped during the three stages of growth (Figure 33A-C). Without BPEI, the bacteria 
typically produce individual rods 1 μm in diameter and 2-3 μm in length. In the 
presence of BPEI, the bacteria produce cells which appear to grow without dividing. 
Rather than producing straight filaments, the cells have sharp twists and bends 
accompanied with an increase in diameter (Figure 34). We are uncertain of why this 
morphological change happens in the presence of BPEI but believe that WTA and LTA 
are involved. 
 
Figure 33. Changes in morphology of B. subtilis due to exposure to BPEI during 
growth, observed using phase contrast microscopy. Cells not grown in BPEI (A-C) have 
a short, rod-shaped morphology. Cells grown in 128 μg/mL BPEI (D-F) have an 
elongated, curling morphology. Images on the left (A, D) were grown to an OD600 of 
~0.2. Middle images (B, E) were grown to an OD600 of ~0.5. Images on the right (C, F) 




Figure 34. SEM images show the curling morphology of B. subtilis 6051 cells grown in 
BPEI. Cells were grown in the absence of BPEI (left) and in the presence of 150 μg/mL 
BPEI (right). The images were taken in early exponential phase of cell growth. Growth 
in the presence of BPEI shows a curling and twisting morphology that lacks septa 
formation. Scale bars equal 5 μm.  
 
 WTA is nonessential for survival in B. subtilis cells. Deletion of the tagO gene, 
codes for the enzyme responsible for the first step of WTA synthesis, causes B. subtilis 
cells to have a decreased growth rate and a rounded, thickened morphology in 
comparison to the wild-type strain.(132) Removal of LTA in B. subtilis elongates the 
bacteria which suggests that LTA is important for localization of cell division 
proteins.(133) B. subtilis bacteria grown in BPEI displayed characteristics similar to 
WTA and LTA-deficient cells such as elongation and thickening of the cells and 
clumping. This effect could be due to BPEI’s interaction with WTA. Binding of BPEI 
to LTA may explain the elongated morphology of the B. subtilis cells grown in BPEI. 
These data suggest that BPEI is interrupting fundamental biochemical processes in the 
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bacterial cell wall. WTA is important in localization of cell wall machinery. D’elia et al. 
presented TEM images that showed that WTA knockout B. subtilis mutants could not 
form proper septa and also had asymmetrical thickening of the cell wall.(132) Schirner 
et al. found that B. subtilis cells grown in targosil, a drug that prevents a late step of 
WTA synthesis, have a reduced amount of MreB filaments.(133) MreB and Mbl are 
actin-like filaments that create the rod-shaped morphology in B. subtilis and knockout 
mutants of these filaments have morphological defects similar to cells grown in 
BPEI.(169) It has been suggested that WTA may be important for localization of MreB 
but the mechanism is not understood.(170) Our hypothesis is that BPEI binding to WTA 
or LTA prevents proper function of MreB or Mbl which causes dramatic morphological 
distortions of B. subtilis cells. 
 
BPEI prevented autolysis of MRSA cells 
 Bacterial cells use autolysins to lyse peptidoglycan strands during cell division, 
allowing separation of daughter cells. The importance of WTA and LTA in the 
regulation of autolysin activity is well known. Schlag et al. found that autolysis 
increased in WTA knockout mutants and proposed that mature WTA prevents binding 
of Atl, an autolytic protein in S. aureus, to the mature cell wall.(142) WTA knockout 
mutants were unable to correctly localize Atl to the division septum.(142) Campbell et 
al. suggest that when WTA is absent, inefficient septal formation occurs due to the 
degradation of the autolysins track that allows for cell separation.(139) Triton X-100 
induced autolytic rate measurements were performed to determine if BPEI affects 
autolysis in MRSA 700787. The autolytic rate of MRSA cells grown in 16 μg/mL of 
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BPEI was slowed in comparison to control samples (Figure 35). Autolysis was 
completely stopped for MRSA cells grown in 64 μg/mL of BPEI. Due to a larger initial 
cell density (~1 x 10
8
 CFUs/mL), the concentration of BPEI used was higher than the 
MIC found in the checkerboard assays (~5 x 10
5
 CFUs/mL). Triton X-100 induced 
autolysis is believed to occur via the release of LTA from the cell wall.(171) The origin 
of BPEI-induced slowing of autolysis is unknown, but a possible explanation is the 
prevention of LTA release by the electrostatic binding of BPEI to LTA, which causes 
steric restraint and prevents Atl localization. Further work is necessary to test this 
hypothesis. 
 
Figure 35. BPEI prevents Triton X-100 induced autolysis in MRSA 700787 in a 
concentration dependent manner. As the concentration of BPEI increased, the rate of 
autolysis decreased. Data points are presented as the average of three trials and error 
bars denote the standard deviation. 
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WTA-deficient knockout mutants have altered cell wall structure and cell division 
 Bacteria morphology, cell wall, and division septum are altered when WTA is 
inhibited or absent because WTA is important for localization of cell wall proteins. 
WTA-deficient mutants of MRSA have thicker cell walls. Additionally, the division 
septa of WTA-deficient mutants tend to have multiple formations, be asymmetrical, and 
lack full expansion or separation.(139, 142) These observations are confirmed here. 
Normally, MRSA MW2 is cocci-shaped with one division septum spanning through the 
center of the cell (Figure 36A). MRSA MW2 ΔtarO, a mutant that lacks WTA, had 
many septa formations on one cell (Figure 36B). The multiple septa are also at 
asymmetric and abnormal angles. Additionally, the widths of the septa appear thicker in 
comparison to the wild-type cells. The wild-type cells (Figure 36) display unaltered cell 
walls and division septa. The images seen here correspond to the literature data that 
show MRSA MW2 ΔtarO with altered cell morphology and division septa in 
comparison to the wild-type strain. The data here shows the impact that affecting WTA 
has on the morphology of MRSA. Thus, we were motivated to determine if 
electrostatically binding to WTA would have a similar effect on cell division. 
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Figure 36. A WTA-deficient mutant, MRSA MW2 ΔtarO has altered cell division 
compared to the wild-type cell. Normal, wild-type MRSA MW2 is cocci shaped with a 
single division septum across the center (A). MRSA MW2 ΔtarO has multiple division 
septa found on one cell, and the septa are thicker (B). Scale bars equal 200 nm. 
 
BPEI increased cell size of MRSA 
 WTA-deficient mutants have altered morphologies. SEM images at mid-
exponential phase showed that a WTA-deficient mutant was significantly larger and had 
a rougher surface than the wild-type cells.(142) We were motivated to determine if 
BPEI caused any morphological changes in MRSA. MRSA 700787 cells were grown in 
sub-lethal concentrations of BPEI, isolated at late-lag phase, and imaged. SEM images 
show that BPEI does not dramatically alter the shape of MRSA 700787. However, the 
size of the cells was significantly increased (p-value < 0.001) from 0.86 ± 0.11 μm to 
0.98 ± 0.14 μm when grown in BPEI, and the numerous MRSA aggregates suggest the 
inability to properly form septa and complete the cell division process (Figure 37). The 
cell morphologies do not appear to be significantly altered; however, the cleavage 
furrow does not form properly for the cells treated with BPEI. The phenotypic similarity 
between cells grown in BPEI and knockout mutant cells suggests that the altered 
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morphologies may arise from an interaction between BPEI and WTA. This data 
combined with the autolysis data confirm that BPEI prevents cell wall machinery from 
functioning properly. 
 
Figure 37. BPEI caused a significant increase in MRSA 700787 cell size. The average 
cell size (largest diameter) for untreated cells is 0.86 ± 0.11 μm (A) but increases to 
0.98 ± 0.14 μm when grown in 64 μg/mL BPEI (B). Normal cleavage furrows are 
shown with black arrows. Enlarged cells that do not have cleavage furrows present are 
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shown with white arrows. Cells were fixed and imaged at late-lag phase. Scale bars 
equal 1 μm. A size analysis graph (C) shows the average cell size (center line), the 
standard deviation (outside of box), and minimum and maximum values (error bars) of 
100 measured cells. (p-value <0.001) 
 
Cell division was altered when cells were treated with BPEI 
 TEM was used to look at the intracellular area and cross-section of the bacterial 
cells to determine if BPEI affected the cytoplasmic area, cell wall, or division septum. 
Negative effects to the division septum were seen when MRSA 700787, MRSA 
USA300, and MRSA MW2 were treated with sub-inhibitory concentrations of BPEI. 
However, each strain is phenotypically distinctive from one another. Approximately 
25% of untreated MRSA 700787 cells were found to have two septa in dividing cells 
(Figure 38A). In each case, the first septum is fully complete and the second septum is 
at the initial stage of septa formation and perpendicular to the first. This type of septa 
formation was unique to MRSA 700787 and not found in untreated MRSA USA300 or 
MRSA MW2. When treated with BPEI, approximately 35% of MRSA 700787 cells had 
cell septa abnormalities including multiple completed septa on each cell or non-
perpendicular septa (Figure 38B). Only 7% of untreated bacteria have division septa 
that would be classified as abnormal. The bacteria were visually larger (Figure 37), as 
seen with SEM. The large cell sizes of BPEI-treated MRSA 700787 cells seen on SEM 
images were supported by the absence of septal indents shown in the TEM images. This 
gives the appearance of each cell being larger because the septa cannot be clearly seen 
extracellularly. These data clearly show that BPEI impacts the development of the 




Figure 38. MRSA 700787 cells have abnormal cell division when grown in BPEI. 
Untreated cells (A) show normal cell division septa versus treated cells (B). Black 
arrows indicate complete septa formation. White arrows indicate incomplete septa 
formation. Scale bars equal 200 nm.  
  
 MRSA USA300 cells treated with BPEI had difficulty dividing. SEM images of 
treated versus untreated cells do not show drastic changes in cells morphology, but the 
BPEI-treated cells contain multiple cell division septa that are not seen in control cells. 
(Figure 39) When examined using TEM, treated cells were found to have visibly thicker 
division septa and the electron density of the division septa was lower for the treated 
cells compared to the control cells (Figure 40). Also, the percentage of cells that were in 
active cell division was higher for treated samples in comparison to the untreated 
samples (Table 11). For untreated samples, 75% of cells did not have a visible septum, 
12% had a complete septum, and 13% had incomplete septa. For treated samples, only 
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53% of cells had no septum, 24% had complete septa, and 23% had incomplete septa. 
These data suggest that cells are unable to separate efficiently. 
 
Figure 39. SEM of MRSA USA300 shows multiple septa formations when treated with 
BPEI. Untreated cells (A) have a single septal formation (black arrows). Some BPEI-




Figure 40. TEM images of MRSA USA300 cells do not show drastic changes in 
division septa.  Cells treated with BPEI (B and D) have thicker division septa in 
comparison to the untreated cells (A and C). Black arrows indicate complete septa 
formation. White arrows indicate incomplete septa formation. Scale bars equal 500 nm.  
 
Table 11. BPEI prevents MRSA USA300 cells from separating efficiently.  
 Untreated (%) Treated (%) 
No Visible Septa 75% 53% 
Complete Septa 12% 24% 
Incomplete Septum 13% 23% 
Notes: 200 cells from each sample were analyzed from TEM images to determine the 
level of septal formation. 
BPEI degraded the cell wall and caused stress response 
 All strains tested had a different response to treatment with BPEI. MRSA MW2 
had an overall stress response to treatment with BPEI. TEM images show that untreated 
MRSA MW2 cells have a dark, thin cell wall with a clear septum formation (Figure 
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41A). The septa region is dark in the control cells because the WTA-rich region 
strongly attracts the metal cations that are used to stain the samples. When treated with 
BPEI, the bacteria have altered cell division septa and lighter staining septa (Figure 
41B). The light septum staining in the treated samples indicates that the amount of 
WTA found in the septum region is lower than normal. Additionally, the cell wall 
surface is rougher for treated cells (Figure 41D) in comparison to the untreated cells 
(Figure 41C). MRSA MW2 cells show signs of universal stress. Stress in bacteria can 
be caused by a variety of issues including osmotic pressure, nutrient starvation, high or 
low pH, high cell density, or the presence of toxic chemicals.  
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Figure 41. BPEI causes MRSA MW2 to show signs indicative of cell stress. TEM 
images of untreated (A) and BPEI-treated (B) show the difference in cell wall 
composition and septum formation. Scale bars equal 200 nm. SEM images of untreated 





 It has been well established that removal of WTA through genetic or chemical 
means compromises cell morphology and cell division in MRSA and B. subtilis 
bacteria. However, artifacts could arise from gene deletion or by inhibiting the initial 
steps of WTA synthesis chemically. Therefore, the importance of WTA in cell 
morphology due to immature WTA, WTA-synthesis machinery, or mature WTA could 
not be determined. The method for preventing WTA-function changes the morphology 
outcome. WTA inhibition through genetic modification caused many septa to 
form.(139, 142) Also, septa formations on these cells were at parallel or non-
perpendicular angles. Targosil, which inhibits a late step of WTA synthesis by blocking 
TarG, creates defects that are likely caused by osmotic stress and cell membrane 
damage. Targosil-treated cells are unable to separate and form increasing cell and 
cluster size as growth time continues.(163) Tunicamycin, which blocks the first-step of 
WTA synthesis by inhibiting TarO, have global effects to cell division resulting in 
multiple septa formations, asymmetric septa, and incomplete septa.(139) Removal of 
LTA creates irregularities to the cell such as thickened wall and impaired cell division 
which are thought to be due to reduced autolysis activity.(172) BPEI does not target 
WTA-synthesis. However, BPEI electrostatically binds to WTA creating steric 
hindrance and effectively disabling the mature WTA. Here we show that BPEI caused 
dramatic morphology changes to B. subtilis. B. subtilis cells that were treated with sub-
lethal BPEI formed elongated, twisting, and curling cells. Against MRSA, the effects of 
BPEI on cell morphology were less pronounced. However, BPEI increased cell size, 
prevented the cells from dividing properly, and created cell wall destruction. Autolysis 
118 
data showed that BPEI prevents autolysis in MRSA cells. Although removal of WTA 
through genetic manipulation causes more drastic effects to the division septum of 
dividing MRSA cells, BPEI prevents MRSA from dividing properly. These data reveal 
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[Appendix A: Table of Abbreviations] 
Abbreviation Explanation 
ANOVA Analysis of variance 
BSL Biosafety level 
BPEI Branched polyethylenimine 
CA-MRSA 
Community-acquired methicillin-resistant Staphylococcus 
aureus 
CFU Colony-forming unit 
COSY Correlation spectroscopy 
Da Dalton 
DNA Deoxyribonucleic acid 
EPS Extrapolymeric substance 
FDA Food and Drug Administration 
FIC Fractional inhibitory concentration 
FICI Fractional inhibitory concentration index 
GFP Green fluorescent protein 
HA-MRSA Hospital-acquired methicillin-resistant Staphylococcus aureus 
HMBC Heteronuclear multiple-bond correlation spectroscopy 
HMDS Hexamethyldisilazane 
hRPTECs Primary human renal proximal tubule epithelial cells 
HSQC Heteronuclear single-quantum correlation spectroscopy 
IC50 Half maximal inhibitory concentration 
LB Lysogeny broth 
LDH Lactase dehydrogenase 
LPEI Linear polyethylenimine 
LPS Lipopolysaccharide 
LSCM Laser scanning confocal microscope 
LTA  Lipo teichoic acid 
MBC Minimum bactericidal concentration 
MIC Minimum inhibitory concentration 
MRSA  Methicillin-resistant Staphylococcus aureus 
MSSA Methicillin-susceptible Staphylococcus aureus 
MW Molecular weight 
NA Numerical aperture 
NAG N-acetylglucosamine 
NAM N-acetylmuramic acid 
NMR Nuclear magnetic resonance 
OD600 Optical density at 600 nm 
PBP Penicillin binding protein 
PBS Phosphate buffered saline 
134 
PEI Polyethylenimine 
PO Propylene oxide 
PVL Panton–Valentine leukocidin 
RO5 Rule of 5 
SCCmec Staphylococcal cassette chromosome mec 
SEM Scanning electron microscope 
TCA Trichloroacidic acid 
TEM Transmission electron microscope 
TOCSY Two-dimensional nuclear magnetic resonance spectroscopy 
TSB Tryptic soy broth 
VISA Vancomycin-intermediate-resistant Staphylococcus aureus 
VRSA Vancomycin-resistant Staphylococcus aureus 
WTA Wall teichoic acid 
YFP Yellow fluorescent protein 
 
 
